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1  Abbreviations 
 
2-OG  2-oxoglutarate 
AhR  aryl hydrocarbon receptor 
ANG  angiogenin 
ANGPT angiopoietin 
AREG amphiregulin 
ARNT  AhR nuclear translocator 
BMDC bone-marrow derived cells 
BPD  bronchopulmonary dysplasia 
CAC  circulating angiogenic cells 
CAIX  carbonic anhydrase IX 
CLI  critical limb ischemia 
CO2  carbon dioxide 
CREB  cyclic AMP response element binding protein 
DFO  desferrioxamine 
DMOG dimethyloxaloylglycine 
ED  embryonic day 
EGFR  epidermal growth factor receptor 
EGL-9 egg-laying abnormal 9 
EGLN  egl nine homolog 
EPAS  endothelial PAS protein 
EPO  erythropoietin 
FGF  fibroblast growth factor 
FIH  factor inhibiting HIF 
GBM  glioblastoma multiforme 
GLUT1 glucose transporter 1 
GOF  gain of function 
Hb  hemoglobin 
Hct  hematocrit 
HIF  hypoxia-inducible factor 
HNSCC head and neck squamous cell carcinoma 
HPH  HIF prolyl-hydroxylase 
ABBREVIATIONS 
-2- 
HRE  hypoxia-responsive element 
IL-8  interleukin-8 
KM  Michaelis constant 
L-Mim L-mimosine 
MUC1  mucin1 
NF-κB nuclear factor κB 
NO  nitric oxide 
ODD  oxygen-dependent degradation 
PAS  Per/ARNT/Sim 
PDAC  pancreatic ductal adenocarcinoma 
PDGF  platelet-derived growth factor 
PHD  prolyl-hydroxylase domain enzyme 
PlGF  placental growth factor 
pO2  oxygen partial pressure 
pVHL  von Hippel-Lindau protein 
RELA  v-rel reticuloendotheliosis viral oncogene homolog A 
RNAi  RNA-interference 
ROS  reactive oxygen species 
RTK  receptor tyrosine kinase 
SCF  stem cell factor 
SDF1  stromal derived factor 1 
shRNA short-hairpin RNA 
UTR  untranslated region 
VEGF  vascular endothelial growth factor 
VEGFR vascular endothelial growth factor receptor 
WISP  wnt-inducible signaling protein 
WRE  WT1 response element 
Wt  wild type 
WT1  Wilms tumor suppressor 1 
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2  Zusammenfassung 
 
Die reduzierte Gewebe-Sauerstoffversorgung (Hypoxie) ist eine bekannte 
Eigenschaft der meisten soliden Tumoren. Tumor Hypoxie ist assoziiert mit erhöhter 
Bösartigkeit, erhöhter Zellmigration und Invasion, verstärkter Angiogenese sowie mit 
einer höheren Resistenz gegen Chemo- und Radiotherapie. Die molekularen 
Änderungen die zu einer zellulären Hypoxieadaptation führen, werden grösstenteils 
durch heterodimerische Hypoxie-induzierbare Faktoren (HIFs) gesteuert. Es wurde 
gezeigt, dass die HIFs und die meisten ihrer Zielgene eine wichtige Rolle in der 
Krebsentstehung spielen. Degradation der α  Untereinheit des HIF 
Transkriptionsfaktors wird durch molekularen Sauerstoff messende Eiweisse 
reguliert, die so genannten Prolyl-4-Hydroxylase Domäne Proteine (PHDs). Die drei 
bekannten PHD Isoformen (PHD1, 2, 3) hydroxylieren die α Untereinheit in 
Anwesenheit von molekularem Sauerstoff (O2). Es wurde gezeigt, dass die 
hydroxylierte HIF-α Untereinheit an einen E3-Ubiquitin-Ligase Komplex bindet, der 
als Erkennungsuntereinheit das von-Hippel-Lindau Tumorsuppressorprotein (pVHL) 
beinhaltet. Die Interaktion mit pVHL führt zur proteasomalen Degradation. Unter 
hypoxischen Bedingungen findet wegen des Mangels an Sauerstoff keine 
Hydroxylierung statt. Als Folge davon wird die HIF-α Untereinheit stabilisiert und 
migriert in den Zellkern, wo sie mit der stabil exprimierten HIF-β Untereinheit 
heterodimerisiert. Das Binden des HIF-Heterodimers an spezifische DNS 
Sequenzen, die so genannten Hypoxie „responsive“ Elemente (HREs), führt zur 
Transaktivierung von Zielgenen.  
Um den Beitrag von PHD2 in der Krebsentstehung und Entwicklung zu untersuchen, 
haben wir PHD2 short-hairpin (sh)RNS Klone in MCF-7 Brustkrebszellen generiert. 
Die Resultate von in vivo Xenograft Versuchen in Nacktmäusen zeigen, dass PHD2 
Herunterregulierung in MCF-7 zu schneller wachsenden Tumoren führt. Die 
Rekonstitution von PHD2 in den knock-down Klonen führte zu einer deutlichen 
Abnahme des Tumorwachstums. Die in vitro Zellproliferation wurde nicht von der 
PHD2 Menge beeinflusst. Gewebe Mikroarray Analysen der PHD2 Expression in 
281 klinischen Brustkrebsproben zeigten eine signifikant reduzierte Überlebenszeit, 
über eine Zeitspanne von zehn Jahren, bei Patientinnen mit niedrigen PHD2 Protein 
in den Tumoren.  
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Die Analyse von PECAM-1 Färbungen auf gefrorenen Tumorschnitten zeigte, dass 
sowohl die Blutgefässdichte, als auch der Blutgefässdurchmesser und die 
Blutgefässoberfläche in den shPHD2 Tumoren erhöht waren. Um diesen 
angiogenetischen Phänotyp weiter zu untersuchen und um Unterschiede in der 
Sekretion von angiogenetischen Faktoren festzustellen, wurde 
Zellkulturmediumüberstand von MCF-7 Wildtyp Zellen, shPHD2 und von 
rekonstituierten PHD2 Klonen in einem humanen Angiogenesearray getestet. Der 
vaskuläre Endothel Wachstumsfaktor A (VEGF-A) war in den PHD2 
hinunterregulierten Zellen im Vergleich zu den Wildtyp und rekonstituierten Klonen 
induziert. Dies deutet auf eine Aktivierung des klassischen HIF-Signalwegs hin. 
Ebenso waren auch die Mengen an Interleukin-8 (IL-8) und Amphiregulin (AREG) 
durch die PHD2 Menge beeinflusst, mit einer höheren Expression bei Abwesenheit 
von PHD2 und einer tieferen Expression nach PHD2 Rekonstitution.  
Sowohl AREG mRNS Mengen als auch AREG Promoteraktivität waren in 
Abwesenheit von PHD2 erhöht und wieder tiefer nach PHD2 Rekonstitution. Wir 
konnten weiter zeigen, dass der PHD2 Effekt von der PHD2-Hydroxylierungsaktivität 
unabhängig ist und dass AREG mRNS Mengen nicht durch Hypoxie beeinflusst 
werden. Funktionell konnten wir zeigen, dass AREG die in vitro Gefässbildung 
positiv beeinflusst. Die AREG mRNS Menge sowie die Promoteraktivität werden 
durch HIF-2α aber nicht durch HIF-1α Expression beeinflusst.  
Aus unseren Versuche entnehmen wir, dass PHD2 ein potentieller Tumorsuppressor 
sein könnte und dass die AREG-Regulation durch PHD2 und HIF-2α wichtig für das 
Brustkrebswachstum sein könnte. Weiter haben wir uns auf AREG und wnt-
induzierbares Signalprotein (WISP) 2 konzentriert, beides spezifische HIF-2α 
Zielgene. Die Überlebenszeit von Brustkrebspatientinnen war deutlich verbessert bei 
gleichzeitiger AREG und WISP2 Expression im Tumor. Im Brustkrebs konnte eine 
starke Korrelation zwischen AREG, WISP2 und HIF-2α festgestellt werden. Eine 
detaillierte AREG-Promoter Analyse zeigte, dass mehrere Teile für den HIF-2α 
vermittelten Effekt nötig sind. Funktionell wurde in shHIF-2α Zellen eine reduzierte 
Phosphorylierung der Mitglieder der epidermalen Wachstumsfaktorrezeptor Familie 
(EGFR) beobachtet, im Vergleich zu Wildtyp und shHIF-1α Zellen. Die 
Phosphorylierung konnte durch Zugabe von exogenem AREG wieder rekonstituiert 
werden.  
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Zusammenfassend konnten wir zeigen, dass PHD2 und HIF-2α durch AREG-
abhängige Angiogeneseinduktion und EGFR Aktivierung zum 
Brustkrebsmetabolismus beitragen können. Die Frage, ob PHD2 und HIF-2α im 
gleichen Signalweg agieren oder unterschiedliche Zielgene haben, lässt sich aber 
noch nicht endgültig beantworten. 
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3  Summary 
 
Reduced tissue oxygenation (hypoxia), a characteristic feature of most solid tumors, 
is associated with increased malignancy, enhanced cell migration and invasion, 
increased angiogenesis as well as resistance to chemo- and radiotherapy. Cellular 
adaptation to hypoxia is mainly triggered by heterodimeric hypoxia-inducible factors 
(HIFs). HIFs and many of their target genes were shown to be implicated in the 
malignant progression of cancer. Degradation of the α subunit of the HIF 
transcription factor is regulated by molecular oxygen-sensing proteins, named prolyl-
4-hydroxylase domain proteins (PHDs). The three known PHD isoforms (PHD1, 2 
and 3) hydroxylate the HIF-α subunit in the presence of molecular oxygen (O2). The 
hydroxylated HIF-α subunit was shown to bind an E3 ubiquitin ligase complex, 
containing as a recognition subunit the von Hippel-Lindau tumor suppressor protein 
(pVHL). Interaction with pVHL leads to proteasomal degradation. Under hypoxic 
conditions, lack of oxygen causes hydroxylation to cease. Therefore, the HIF-α 
subunit becomes stabilized and translocates to the nucleus where it heterodimerizes 
with the constitutively expressed β subunit. Binding of the HIF-heterodimer to 
specific DNA sequences, named hypoxia-responsive elements (HREs), triggers the 
transactivation of target genes. 
To study the role of PHD2 in tumor formation and progression, we generated stable 
PHD2 short-hairpin (sh)RNA knock-down clones in MCF-7 breast cancer cells. 
Results obtained from in vivo xenografts experiments in nude mice suggest that 
PHD2 down-regulation in MCF-7 cells leads to faster growing tumors. Reconstitution 
of PHD2 in the MCF-7 knock-down clones abolished this effect. Importantly, in vitro 
proliferation was not affected by PHD2 levels. Conversely, tissue microarray 
analysis of PHD2 expression in 281 clinical samples of breast cancers showed 
significantly reduced survival over a period of ten years, in patients having low level 
PHD2 tumors, suggesting that PHD2 functions as tumor suppressor. 
Analysis of PECAM-1 stainings in tumor sections revealed higher vascularization in 
tumors derived from shPHD2 cells. To further investigate the observed angiogenic 
phenotype and to determine differences in the secretion of angiogenic factors, 
conditioned media from parental MCF-7 cells, shPHD2 clones and reconstituted 
PHD2 clones were tested in a human angiogenesis array. Vascular endothelial 
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growth factor A (VEGF-A), interleukin-8 (IL-8) and amphiregulin (AREG) protein 
levels were found to be affected by PHD2 levels, with higher expression in the 
absence of PHD2 and decreased expression after PHD2 reconstitution.  
AREG mRNA levels as well as AREG promoter activity were found to be increased 
in the absence of PHD2 and decreased again after PHD2 reconstitution. In addition, 
the PHD2 effect was shown to be independent of PHD2 hydroxylase activity and 
AREG mRNA levels were not altered by hypoxia. Functionally, we could show that 
AREG positively influences in vitro tube formation. AREG mRNA levels as well as 
promoter activity were found to depend on HIF-2α but not HIF-1α expression. 
From our experiments we conclude that PHD2 is a potential tumor suppressor in 
breast cancer and that AREG regulation by PHD2 as well as HIF-2α might contribute 
to breast tumorigenesis. Furthermore, we concentrated on AREG and wnt-inducible 
signaling protein (WISP) 2 as specific HIF-2α target genes. Survival of breast cancer 
patients was significantly improved by the concomitant expression of AREG and 
WISP2. Moreover a strong correlation was found between AREG, WISP2 and HIF-
2α in breast tumors. Analysis of the AREG promoter led to the conclusion that 
multiple sites are necessary to mediate the HIF-2α effect on AREG transcription. 
Functionally, a decreased phosphorylation of epidermal growth factor receptor 
(EGFR) family members was observed in HIF-2α deficient cells compared to HIF-
1α deficient cells and parental MCF-7 cells. Phosphorylation of EGFR family 
receptors in HIF-2α cells was rescued by addition of exogenous AREG.  
Summarizing, we conclude that PHD2 and HIF-2α contribute to breast cancer 
metabolism by affecting angiogenesis as well as EGFR signaling in an AREG-
dependent manner. However, if PHD2 and HIF-2α act on the same pathway or have 
different targets is not yet clear. 
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4  Introduction 
 
4.1 Hypoxia and hypoxia tolerance in mammals 
 
4.1.1 Hypoxic environments 
 
Hypoxia is defined as a reduced oxygen partial pressure (pO2) that causes a 
reduction in oxygen availability to body tissues. In general, mammals experience 
hypoxia during diving, hibernation or burrowing. For human beings exposure to 
hypoxia is usually correlated to a stay in the mountains at high altitudes. Additionally, 
hypoxia plays an important role during development. Responses to hypoxia can be 
acute, meaning that they will take place within seconds to minutes or chronic, 
meaning that they will last for hours or days. Many physiological adaptations to 
hypoxia, like differential vasoconstriction, bradycardia, and hypometabolism are 
shared among all mammals. Hypoxia tolerance is achieved through a complex 
reorganization, coordination and partial shut-down process of different organs1.  
 
4.1.2 Adaptation to acute hypoxia 
 
In diving mammals, ventilation stops immediately causing a continuous decrease in 
arterial oxygen and a parallel increase in arterial carbon dioxide (CO2)2. All diving 
animals have an increased oxygen storing capacity in the blood, muscles and lungs. 
In the blood, this is achieved with a high hematocrit (Hct) and high haemoglobin (Hb) 
concentration. The mass of the red blood cells was found to positively correlate with 
diving capacity3. The high oxygen affinity of muscular myoglobin (Mb), present at 
high concentrations, is a useful oxygen store and also provides antioxidant effects4, 
5. Common features in diving animals are high capillary densities in the brain tissue 
as well as a high tidal volume exchange during the brief periods of ventilation that 
enable to rapidly discard CO2 and load oxygen6-8. Since increased oxygen storage 
alone is not sufficient to survive acute hypoxia, animals also have to reduce their 
oxygen requirements, a condition called hypometabolism2, 3. Importantly, 
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neuroprotection and functional integrity need to be guaranteed also under 
hypometabolic conditions. 
 
4.1.3 Adaptation to chronic hypoxia 
 
Adaptation to chronic hypoxia is different from adaptation to acute hypoxia. 
Increased oxygen storage and hypometabolism are not long-term options. The 
strategy to survive chronic hypoxia involves improved oxygen affinity and increased 
oxygen supply. Acclimatization to high altitudes is characterized by carotid body-
mediated hyperventilation to enhance oxygen uptake9, 10, increased cardiac output to 
deliver oxygen to tissues, and erythropoietin (EPO)-induced increase in red blood 
cells (RBC) and subsequent Hb amount11, 12. Interestingly, these short-term 
adaptations to chronic hypoxia are very different from the strategies applied by 
mammals, which permanently live at high altitudes. In fact, to couple high oxygen 
carrying capacity with normal blood viscosity, these adapted animals show low Hb 
and Hct levels, but a high Hb-oxygen affinity13-16.  
 
4.1.4 Pathological hypoxia 
 
From a medical point of view, hypoxia is defined as an abnormal condition in which 
the whole body or single body tissues are deprived of an adequate oxygen supply. 
Hypoxia is a feature of many common pathological conditions such as stroke, 
ischemia, inflammation or cancer. The beginning of the history of research on tumor 
hypoxia can be traced back to the early 20th century when Otto Warburg 
demonstrated that tumor cells favor glycolysis independent of oxygenation levels17. 
In the second half of the past century, hypoxic cells could not yet be visualized, but 
their existence was highly postulated. Observations of necrotic areas in absence of 
capillaries in histological sections of human tumors as well as irradiation 
experiments in mice exposed to different oxygen pressures gave hints for the 
existence of hypoxic cells but direct evidence was missing18, 19. Studies in the 1980s 
and 1990s using 31P-nuclear magnetic resonance (NMR) to monitor cell metabolism, 
misonidazole20, 21 to selectively bind hypoxic cells, electrode measurements and 
cryospectrophotometric measurements of oxyhemoglobin22, confirmed the lower 
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oxygen tension in cancer tissues. The main focus of researchers in the 20th century 
was the role of hypoxia in responses to cancer treatments. Since 1909 it was known 
that cells under hypoxic conditions are less sensitive to radiation, but the changes 
were attributed to differences in blood flow23. Hypoxic radioresistance was 
demonstrated by Gray and colleagues in the 1950s and later confirmed in many 
other studies24. Similarly, common chemotherapeutic agents were shown to be less 
effective against hypoxic cells25, 26. In solid tumours, hypoxic conditions are not only 
associated with resistance to therapies, but also with increased malignancy, 
enhanced invasiveness and angiogenesis. 
 
4.2 Hypoxia-inducible factor (HIF) 
 
4.2.1 The transcription factor HIF 
 
The hypoxia-inducible factor 1 was first described by Semenza and Wang in 199227, 
who observed a factor able to bind the 3’-hypoxia responsive element (HRE) of the 
EPO gene only under hypoxic conditions. Later HIF-1 was shown to be part of a 
wide-spread oxygen-sensing and signal-transduction mechanism28, 29. Purification of 
HIF-1 revealed that it is a heterodimer consisting of an α and a β subunit30. The β 
subunit was found to be identical to the previously identified dimerization partner of 
the dioxin receptor/aryl hydrocarbon receptor (AhR), called AhR nuclear translocator 
(ARNT). Sequencing of the novel HIF-1α subunit led to the identification of a basic 
helix-loop-helix (bHLH) and of a Per/ARNT/Sim (PAS) domain12. Three different α-
subunits (HIF-1α, HIF-2α and HIF-3α) and one β-subunit (HIF-1β) are known so far. 
The HIF-2α isoform is also called endothelial PAS protein 1 (EPAS1). While HIF-
1α is ubiquitously expressed in mice, HIF-2α expression was originally thought to be 
restricted to embryonic and adult endothelium31. The full length splice variant of HIF-
3α is mainly found in the kidney32. 
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4.2.2 Oxygen-dependent regulation of HIF-α subunits 
 
HIF-α protein levels, but not HIF-α mRNA levels are strongly regulated in an 
oxygen-dependent manner. Under normoxic conditions, specific proline residues 
located in the oxygen-dependent degradation (ODD) domain are hydroxylated by the 
HIF prolyl-4-hydroxylases (PHDs). This hydroxylation is a prerequisite for binding of 
the von Hippel-Lindau (pVHL) tumor suppressor protein and subsequent ubiquitin-
dependent degradation of the HIF-α subunits by the 26S proteasome33-36. Normoxic 
HIF-a stabilization due to loss of pVHL was documented in vascular tumors like 
renal clear cell carcinoma, hemangioblastoma and pheocromocytoma35.  
Because of decreased PHDs activity at low pO2, HIF-α subunits become stabilized 
and translocate to nucleus, where they heterodimerize with the constitutively 
expressed HIF-1β subunit. The HIF heterodimer binds to hypoxia responsive 
elements (HRE) and triggers the expression of HIF target genes37. Additionally, 
hydroxylation of a specific asparagine residue in the C-terminal transactivation 
domain of the HIF-α subunit by the factor inhibiting HIF (FIH), interferes with the 
binding of the HIF-α subunit to p300/CBP preventing transcriptional activation of the 
HIF complex38, 39. 
 
4.2.3 Targeted knock-out of HIF subunits 
 
While the genetic ablation of the HIF-3α subunit in mice has not yet been reported, 
the targeted knock-out of HIF-1α and HIF-2α led to partially different and non 
redundant phenotypes. Severe defects in neuronal tube, vascular and pharyngeal 
structures formation as well as in cardiovascular development leading to death at 
embryonic day (ED) 10.5 were observed after loss of HIF-1α40, 41. The developmental 
defects occurring after a HIF-2α targeted knock-out seemed to be restricted to the 
cardiovascular system. In addition, different phenotypes were observed depending 
on the mouse strain used for the experiment. In a C57BL/6 background, loss of HIF-
2α led to embryonic death following defects in cardiac and circulatory functions due 
to reduced catecholamine production42. ICR/129 sv mice lacking HIF-2α presented 
lethal defects during remodelling of the primary vascular network43.  
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4.3 HIF prolyl-4-hydroxylases (PHDs) 
 
4.3.1 The prolyl-4-hydroxylases  
 
The first HIF prolyl-4-hydroxylase was characterized in C. elegans in 200144 and was 
named egg-laying abnormal 9 (EGL-9). Three ortholog isoforms could be identified 
in humans and were named PHD1 (alternatively termed egl nine homolog [EGLN] 2, 
or HIF prolyl-hydroxylase [HPH] 3), PHD2 (EGLN1, HPH2), and PHD3 (EGLN3, 
HPH1). Since these proteins were shown to be able to modulate HIF-α stability in an 
oxygen-dependent manner, they are considered to be the cellular oxygen sensors45, 
46. Alternative splicing variants have been described for PHD247 and PHD348 and a 
shorter PHD1 isoform results from alternative translational initiation49. A fourth PHD-
related protein (PH-4), whose functional relevance is not yet understood, has been 
identified50. Like the collagen prolyl-hydroxylases, also the HIF prolyl-hydroxylases 
belong to the iron and 2-oxoglutarate (2-OG)-dependent family of dioxygenases.  
 
4.3.2 The enzymatic reaction 
 
Molecular oxygen, Fe2+ as well as 2-OG are essential for the PHD catalyzed 
enzymatic reaction to occur. During the enzymatic reaction one oxygen atom is 
transferred to position 4 of a prolyl residue of the substrate forming hydroxyproline. 
The second oxygen atom is utilized for the decarboxylation reaction which will 
convert 2-OG to succinate with formation of CO2 [Figure 1]51. 
 
 
 
 
 
 
 
 
 
  proline     2-oxoglutarate                             4-hydroxyproline     succinate 
Figure 1. The enzymatic reaction catalyzed by HIF prolyl-4-hydroxylases51 
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Furthermore, ascorbate is thought to be needed in vitro for functional catalysis. This 
can be explained with the evidence that ascorbate protects the ferrous iron (Fe2+) in 
the active site from oxidation to ferric iron (Fe3+)52. The PHDs hydroxylate two 
specific proline residues located in the ODD domain  of the HIF-α subunit, namely 
P402 and P564. In vitro, P564 can be hydroxylated by all three isoforms, whereas 
P402 was found to be hydroxylated only by PHD1 and PHD244. However, 
overexpression experiments with all three isoforms in cellular systems showed that 
all of them are active on both proline residues53. Under normoxic conditions 
hydroxylation of P564 is necessary for hydroxylation of P402 to occur. Under 
hypoxic conditions, hydroxylation of P402 starts to be inhibited prior to P564 
hydroxylation. This inhibition of P402 hydroxylation was shown to be already 
sufficient for HIF-α stabilization at low pO2 although P564 hydroxylation was still 
taking place53. In cells, PHDs contribute differentially to HIF-α hydroxylation based 
on their expression levels54. The hydroxylation targets proline residues in a 
conserved LXXLAP motif (X means any random amino acid) of the HIF-α subunit. 
Only the proline in this motif is absolutely necessary for recognition55-57.  
 
4.3.3 Tissue distribution and targeted knock-out of PHDs 
 
The levels of PHD expression in the different organs and tissues is very variable. 
While PHD2 seems to be expressed almost everywhere, peaks of PHD3 expression 
are found in the heart and highest PHD1 expression was detected in testis50, 58. 
Experiments carried out with fluorescent-fusion or tagged proteins at the subcellular 
level, showed that PHD1 was exclusively detected in the nucleus and PHD2 in the 
cytosol. PHD3 was almost equally distributed between the two compartments55, 59. 
However, in rat hepatocytes endogenous PHD2 and PHD3 were both described in 
the cytoplasm as well as in the nucleus60. 
PHD1 and PHD3 knock-out in mice do not affect embryonic survival, whereas a 
targeted disruption of the PHD2 locus causes the death of the embryo, due to 
severe defects in the heart. Heart defects were not accompanied by high HIF−α 
protein levels, suggesting either a compensatory role for the remaining isoforms or 
additional HIF-independent functions of PHD261.  
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4.3.4 PHD - HIF feedback loop 
 
It was shown that PHD2 and PHD3 but not PHD1 are direct HIF targets. As a 
consequence, their mRNA levels were shown to be induced under reduced pO262. 
Proline hydroxylation is an irreversible process and the enhanced hydroxylation that 
takes place following PHD accumulation under hypoxic conditions, accelerates the 
rate of HIF-α degradation during reoxygenation63, 64. This feedback loop is also 
important under conditions of prolonged hypoxia, where increased PHD levels can 
partially compensate for the low pO2 and therefore limit the hypoxic response elicited 
by HIF protein accumulation65.  
 
4.3.5 Factors influencing PHD activity 
 
PHD activity is influenced by various factors. The most important among them is 
oxygen, whose presence is essential for the hydroxylation reaction. Michaelis-
constant (KM) values for all three PHDs were determined by an in vitro hydroxylation-
coupled decarboxylation assay and range between 230-250 µM under normoxic 
conditions, meaning that changes in pO2 can easily affect HIF-α prolyl-
hydroxylation47. These KM values are clearly higher than tissue pO2 providing the 
basis for the PHD catalyzed enzymatic reactions66.  
The prolyl-hydroxylase reaction requires 2-OG, an intermediate of the citric acid 
cycle. However, other metabolites, namely oxaloacetate or pyruvate were shown to 
inhibit the hydroxylation reaction and therefore to promote HIF-α accumulation, by 
occupying the 2-OG binding site 67, 68.  
Like all members of the Fe(II)- and 2-oxoglutarate-dependent dioxygenase family, 
PHDs bind iron with high affinity. In addition to Fe 2+ also other divalent cations, 
namely Cd2+, Ni2+, Mg2+, Mn2+, and Co2+ were shown to have an impact on the HIF 
system69, 70. Cu2+ was shown to interact with the active site of the enzyme displacing 
iron and therefore stabilizing HIF-α under normoxic conditions71. Experiments 
carried out with Ca2+ chelators showed that calcium interferes with PHD2 activity, 
thereby inhibiting its effects72. 
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Another molecule found to mediate HIF-α stabilization through its inhibitory effects 
on PHD activity is nitric oxide (NO), which is derived from different NO donors or 
produced by iNOS. The inhibitory effect might be due to formation of nitrosothiols 
that compete with oxygen or might be due to iron oxidation in the catalytic centre67, 
73, 74. Interestingly, several studies revealed that NO can decrease hypoxia induced 
HIF-1α levels. This bimodal response to NO treatment can be explained by the fact 
that during early phases, in the presence of NO, PHD2 is inhibited and HIF-1α 
subsequently stabilized, whereas later when PHD2 protein levels are increased and 
concomitantly NO is no longer present, HIF-1α levels are again decreased75, 76.  
Reactive oxygen species (ROS) production is increased under hypoxic conditions 
because of inhibition of the respiratory chain. The evidence that antioxidants 
influence the oxygen signalling pathway suggest that ROS might play an important 
role in influencing the HIF system77. Experiments carried out with ascorbate as an 
antioxidant have shown that it can prevent iron oxidation in the catalytic centre of 
PHDs and enhance in vitro hydroxylation of a HIF-α ODD fusion protein construct67, 
78. Two other proteins shown to play a role in the HIF system in association with 
ROS, are mucin 1 (MUC1) and Jun D. MUC1 attenuates HIF-transcriptional activity 
by inducing PHD3 and suppressing ROS accumulation79. The transcription factor 
Jun D, involved in oxidative stress defense, inhibits prolyl hydroxylation by 
increasing hydrogen peroxide (H2O2) metabolism, and consequently iron oxidation80.  
 
4.4 Prolyl-4-hydroxylase inhibitors 
 
The prolyl-hydroxylases are increasingly considered as attractive drug targets for the 
treatment of different pathologies characterized by ischemia, inflammation or kidney 
failure. Based on studies showing that PHD2 can be a key regulator of HIF-driven 
angiogenesis81, prolyl-hydroxylase inhibitors became of interest as potential 
therapeutic angiogenesis inducers. 
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In this context, it should not be forgotten that loss of PHD2 leads to death during 
mice development meaning that PHD inhibition has to be carefully modulated82. 
Newly designed inhibitors were shown to interfere with various domains of the 
protein such as its protein-protein interaction domain, the catalytic domain or, to 
increase specificity, with isoform-specific domains [Figure 2]83.  
 
4.4.1 Non-selective PHD inhibitors  
 
The catalytic site of the prolyl-hydroxylases can be inhibited either by compounds 
that structurally mimic 2-OG and therefore block the entry of the substrate or by iron-
chelating compounds. Isoform specificity is not achieved with these compounds 
since 2-OG docking to the active site relies on amino-acids, which are highly 
conserved among the prolyl-hydroxylases (see Table 1 in reference83). Iron-
chelation will also interfere with other enzymes having iron in their catalytic centre 
leading to undesired side-effects. Other metal ions such as Co2+, Cu2+, Zn2+ and 
Mn2+ are not able to support PHDs enzymatic activity and can therefore also function 
as inhibitors84. 
To overcome the disadvantage of missing selective isoform inhibition, new 
compounds based on aromatic heterocycles related to pyridine derivatives, like 8-
hydroxyquinolines are being developed85. Co-crystallization experiments with PHD2 
showed promising interaction between these compounds and the enzyme86.  
Figure 2. Targets of PHD-inhibitors83
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4.4.2 Alternative approaches of PHD inhibition  
 
Apart from the catalytic site, which is strongly conserved among PHDs, other 
domains like the amino- or the carboxy- terminal end, which show higher variability 
could be targeted. In fact two β-strands determine selectivity of PHDs for the N- or 
C- ODD. Since PHD3 seems to preferentially hydroxylate the CODD, while PHD2 
hydroxylates both, inhibitors targeting this domain could enhance isoform-
selectivity87. In addition, novel inhibitors could also target specific interaction 
partners like the isomerase FKBP38 that was shown to decrease PHD2 stability88 or 
mitogen-activated protein kinase organizer 1 (MORG1) that was described as a 
scaffold protein for PHD389.  
 
4.5 Angiogenesis 
 
While vasculogenesis is defined as the de novo formation of blood vessels from 
endothelial cell precursors called angioblasts, angiogenesis describes the process of 
growth of new blood vessel from existing ones. Arteriogenesis is a remodelling of 
blood vessels, which results in an increased luminal diameter and a subsequent 
increase in blood flow. Angiogenesis is an essential physiological process especially 
during organ development. In adults, angiogenesis is mainly restricted to the female 
reproductive system, to organs undergoing physiological growth and to wound 
healing. Imbalanced angiogenesis is a common feature of numerous inflammatory, 
malignant, ischemic, infectious and immune disorders. Nowadays anti-angiogenic 
compounds are used to treat tumors and blindness.  
 
4.5.1 Angiogenic switch 
 
In addition to all genetic and epigenetic changes leading to tumor progression, 
another step is required for cancer cells to proliferate and expand: the induction of a 
tumor vasculature termed the angiogenic switch [Figure 3]90. In fact, the generation 
of a functional tumor blood supply is a critical step in tumor progression. Induction of 
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the angiogenic switch depends on the balance between pro-angiogenic stimuli and 
angiogenesis inhibitory effects and can occur at different stages of tumor 
progression91.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5.2 Tumor angiogenesis 
 
In contrast to normal physiological angiogenesis where blood vessels rapidly mature 
and become stable, tumor angiogenesis leads to vessels which fail to completely 
develop and become quiescent. Tumor vessels are irregularly shaped, dilated and 
present dead ends lacking a typical organization in venules, arterioles and 
capillaries. These chaotic features make the tumor vascular network leaky and 
hemorrhagic. In addition, perivascular cells, which usually line the endothelium are 
Figure 3. The angiogenic switch90
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loosely associated and less abundant in tumor vessels92, 93. Even cancer cells were 
found to be intercalated in the vessel walls94, 95. In addition, some tumors mainly rely 
on vasculogenesis through recruitment of bone marrow-derived endothelial 
precursor cells rather than classical angiogenesis96. 
 
4.5.2.1 Formation of tumor blood vessels 
Although the vasculogenesis process can be adapted for the use by tumors, with 
endothelial precursor cells mobilized from the bone marrow and transported to the 
walls of growing blood vessels, most tumor neovascularization occurs via 
angiogenesis97. In the first stage of angiogenesis, existing capillaries dilate and 
increase their permeability in response to VEGF, which was shown to be sufficient 
for the induction of angiogenesis in a quiescent vasculature98. Increased 
permeability allows extravasation of plasma proteins that form a provisory matrix on 
which endothelial cells can migrate98. While targeted degradation of the matrix and 
of the basement membrane allows endothelial cells to migrate, their continuous 
proliferation leads to enlargement of the blood vessel diameter. The decreased 
vessel association with pericytes in combination with the high production of VEGFA 
might in part explain the abnormal vessel diameters and the sensitivity to anti-
VEGFA therapy92, 99. Recent studies have shown that the role of VEGFA could also 
be taken over by other angiogenic factors like angiogenin (ANG) 100, 101, platelet-
derived growth factor (PlGF)102, fibroblast growth factor (FGF) or other members of 
the VEGF family103. New blood vessels develop at the rim between hypoxic and 
necrotic tumor areas, where the VEGF levels are highest. Although cancer cells 
have a metabolism adapted to hypoxic conditions with an increased glycolysis to 
maintain ATP production104, oxygen supply by blood vessels remains fundamental. 
 
4.5.2.2 Tumor progression through angiogenesis 
Various studies with mouse as well as human tumor models showed that 
angiogenesis can be switched on at different stages of tumor progression depending 
on the cancer type and on the surrounding microenvironment. The angiogenic switch 
was thought to separate two distinct phases in tumor progression; a first avascular 
phase characterized by small dormant lesions and a second one in which a small 
fraction of cancer cells will be able to proliferate, because of the growth of blood 
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vessels. This same principle also applies to metastasis105. The need of blood supply 
for tumor progression was proven in several studies. RipTag mice which develop 
pancreatic islet carcinomas as well as K14-HPv16 mice, used as a model of 
squamous cell carcinoma of skin and cervix, need neovascularization as a 
prerequisite for tumor progression106-110. VEGF was shown to be essential for the 
angiogenic switch in the pancreatic islet tumor model107. Mammary carcinoma prone 
mice (MMTV-neu) lacking the angiogenesis inhibitor thrombospondin-1 (TSP1) were 
found to give rise to bigger, more vascularized tumors111. Importantly, similar results 
were also observed in patients suffering from breast, prostate, and cervix 
carcinomas91. No human tumor bypassing the premalignant stage has been 
described to date.  
 
4.5.2.3 The special case of astrocytomas 
Although in most tumor types neoangiogenesis is an essential condition for further 
proliferation and growth, a type of brain tumors, namely astrocytomas, do not initiate 
angiogenesis during their growth. Blood supply is guaranteed by the alignment along 
existing brain blood vessels. These non angiogenic tumors do not possess a core 
and the tumor mass proliferates along the existing vessels112. Other very aggressive 
tumors, like chondrosarcomas, also present a low vessel density113.  
 
4.5.3 Anti-angiogenic therapy 
 
Several angiogenesis inhibitors have been developed to block tumor angiogenesis 
and therefore slow-down tumor progression. The strategy behind this approach is to 
target cells that support cancer progression, like the endothelial cells forming the 
tumoral vasculature rather than cancer cells themselves.  
 
4.5.3.1 Classes of angiogenesis inhibitors 
Angiogenesis inhibitors can be subdivided into direct and indirect inhibitors [Figure 
4]105. Direct inhibitors target genetically stable endothelial cells preventing them from 
proliferating or migrating in response to pro-angiogenic stimuli. Indirect inhibitors 
block tumor-derived proteins, which induce angiogenesis or block their receptors on 
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endothelial cells. Since direct angiogenesis inhibitors are developed to target 
genetically stable endothelial cells, they are less prone to induce drug resistance114. 
Many of the targets of indirect inhibitors are oncogene products involved in the 
angiogenic switch115-117. In fact, activating mutations in oncogenes have been shown 
to lead to an induction of pro-angiogenic molecules and to a simultaneous down-
regulation of angiogenesis inhibitors115. Certainly of interest is also the fact that 
vascularization of some particular tumors almost entirely rely on a single angiogenic 
factor, like bFGF in giant-cell tumors of the bone and angioblastomas. In addition, 
endogenous angiogenesis inhibitors like thrombospondins can also play an 
important role in the development of future inhibitors118. It has been shown that most 
angiogenesis inhibitors reach their maximal effectiveness when a constant product 
concentration is kept in the circulation119.  
 
4.5.4 Resistance to anti-angiogenic therapy 
 
Although angiogenesis inhibitors have been shown to confer many survival benefits 
to patients bearing aggressive tumors, these compounds failed to produce a long-
term clinical response. Anti-angiogenic treatment unfortunately results in only 
transitory improvements and after a while the tumors will inevitably start to grow 
again.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Mechanism of action of angiogenesis inhibitors105 
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4.5.4.1 Evasion of antiangiogenic therapy 
One of the suggested mechanisms to explain the developing resistance to anti-
angiogenic compounds is the concept of indirect evasive resistance, which is based 
on at least four different adaptations of molecular signaling pathways. 
 
Activation of alternative pro-angiogenic pathways 
In a mouse model of pancreatic neuroendocrine cancer, treatment with a 
monoclonal antibody targeting vascular endothelial growth factor receptor (VEGFR) 
caused an initial reduction in tumor vascularity followed by tumor regrowth. Higher 
levels of alternative pro-angiogenic factors like FGF 1 and 2, ephrin (EFN) A1 and 
A2 as well as angiopoietin 1 (ANGPT1), were found in relapsing tumors, suggesting 
that angiogenic factors other than VEGF were involved in restoring 
vascularization120. A similar mechanism of FGF induced revascularization, in 
particular FGF2, was also observed in a clinical study involving glioblastoma patients 
treated with the VEGFR inhibitor cediranib (Recentin, Astra Zeneca)121. These 
examples show how alternative angiogenic factors can take over once VEGF has 
been successfully inactivated. 
 
Recruitment of vascular progenitor cells from the bone marrow 
Tumor hypoxia can also trigger the recruitment of various bone-marrow derived cells 
(BMDCs) that have the power to initiate revascularization. Pro-angiogenic BMDCs 
comprise vascular progenitors, like endothelial cells and pericytes, as well as 
vascular modulators, like tumor associated macrophages122 and immature 
monocytic cells. Vascular modulators exert their effects by releasing proteases, 
growth factors and cytokines123, 124. Extensive hypoxia and consequent up-regulation 
of HIF-1α were shown to promote angiogenesis due to recruitment of bone marrow 
derived CD45+ myeloid cells in a model of glioblastoma multiforme (GBM). These 
effect was not seen in GBM lacking HIF-1α124, 125. Additional evidence supporting a 
role for hypoxia in BMDCs recruitment came from a study demonstrating that 
vascular disruption triggers accumulation of endothelial cells at the tumor margins126.  
 
Tumor vessel protection through increased pericyte coverage 
Pericytes are also an important element of the tumor vasculature. It is known that 
tumor vessels lacking tight pericyte coverage are more vulnerable to anti-VEGF 
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therapy92, 127. Following impaired vascularization due to anti-angiogenic therapy 
some tumors rely on pericytes to protect and keep alive a core of functional blood 
vessels. Vessels, which survived inhibition of VEGF signaling, exhibited a different 
morphology being tightly covered with pericytes127-132. Pericytes are thought to 
protect the vessels by mediating endothelial cell quiescence and rendering them 
less responsive to therapy. Based on these data, combined targeting of pericytes 
and endothelial cells via inhibition of VEGF and platelet-derived growth factor 
(PDGF) respectively, was shown to improve efficacy of anti-angiogenic treatment in 
several mouse models and is currently tested in clinical trials127, 133, 134. Although the 
idea to dissociate pericytes from blood vessels to render them more susceptible to 
anti-VEGF therapy seemed to be a promising option, several studies showed that 
loss of pericyte coverage causes disruption of vascular integrity facilitating the transit 
of tumor cells into the circulatory system. As an example, increased metastasis as a 
result of pericyte targeting was observed in a murine model of pancreatic 
neuroendocrine tumor135.  
 
Increased invasion without angiogenesis 
Another response to angiogenesis inhibition is an increased invasiveness of cancer 
cells. In a mouse model of GBM in which angiogenesis was inhibited either with 
VEGF inhibitor or genetically blocked by deletion of VEGF, HIF-1α or matrix 
metalloproteinase 9 (MMP9), tumors were shown to be more invasive124, 136, 137. 
These observations were recently confirmed in clinical studies involving GBM 
patients, who developed tumor recurrence following anti-VEGF therapy138, 139. This 
phenotype might be explained via activation of a pre-existing invasion program or via 
a switch to invasive growth due to nutrient deprivation. 
 
4.5.4.2 Indifference to anti-angiogenic therapy 
Resistance to anti-angiogenic therapy could also imply an intrinsic, already existing 
non-responsiveness of tumors. This was observed in a minority of patients, who did 
not respond at all to vascular targeting and whose tumors were continually growing 
during therapy121.  
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Pre-existing multiplicity and redundancy 
In contrast to early-stage breast cancers, late-stage breast tumors were found to 
express many angiogenic factors, including FGF2, different from VEGF. This 
expression pattern could explain, why an anti-angiogenic therapy targeting VEGF, 
would not be of benefit for late stage breast tumors, which switched already on a 
pre-existing alternative angiogenic program140. Nevertheless, anti-VEGF therapy 
was approved for the treatment of late-stage cancer diseases to achieve 
chemosensitization129. Vessel normalization and improved blood flow due to VEGF 
inhibition might in fact facilitate the diffusion of cytotoxic chemotherapeutics. 
  
Pre-existing inflammatory mediated vascular protection 
A recent study performed in mice showed that tumors with a large infiltration of 
inflammatory cells, secreting pro-angiogenic factors, are less responsive to anti-
angiogenic therapies approaches compared to tumors having a less pronounced 
inflammatory cell infiltration. This effect was seen independently of a previous 
applied chemotherapy141, suggesting a role for inflammatory cells and their secreted 
factors in vascular protection. 
 
Characteristic hypovascularity 
Some tumors like pancreatic ductal adenocarcinoma (PDAC) are characterized by a 
typical hypovascularization. Despite an avascular core, these tumors do not present 
necrosis suggesting an adaptation to the hypoxic microenvironment. This intrinsic 
tumor physiology might render PDAC indifferent to anti-angiogenic treatments. 
Clinical trials of anti-angiogenic therapy combined with chemotherapy seem to 
confirm the intrinsic resistance of hypovascular tumors to the treatment142.  
 
Invasion of normal vessels 
A subset of tumors, namely grade II and III astrocytomas, fail to form lesions with a 
prominent vascularized core, where proliferation of endothelial cells takes place. 
Since these tumors do not develop the typical aberrant angiogenic vasculature 
typically targeted by anti-angiogenic compounds, they are suspected not to respond 
to classical anti-angiogenic therapy143. 
 
INTRODUCTION 
-25- 
4.6 The role of HIF in vascularization and vascular remodelling 
 
4.6.1 Angiogenesis and vascular remodelling 
 
A role for HIF in angiogenesis is documented by several in vivo and in vitro studies. 
Although embryos of mice lacking HIF-1α expression normally start vasculogenesis, 
their initial vasculature was shown to degenerate leading to midgestation embryonic 
lethality, suggesting an impairment of angiogenesis or arteriogenesis40, 144.  
Expression of the most critical angiogenic factors including VEGF, stromal derived 
factor 1 (SDF1), ANGPT2, PlGF, PDGFB, and stem cell factor (SCF), was shown to 
be induced by hypoxia through upregulation of HIF-1 and to be cell-type specific145-
150. While direct HIF-1 binding to promoter and activation of transcription has been 
shown for VEGF, SDF1 ANGPT2 and SCF genes145-148, it is not yet clear if HIF-1 
activates PlGF and PDGFB directly or indirectly. High induction of HIF-1 mRNA as 
well as HIF-1 protein levels followed by an increase in mRNA expression of several 
pro-angiogenic factors was observed in mouse ischemic limbs at day 3 after femoral 
artery ligation. These responses were impaired in HIF-1α+/- animals150.  
Secreted angiogenic factors also play a role in the mobilization of pro-angiogenic 
cells from the bone marrow or from other tissues. This population of circulating 
angiogenic cells (CACs) includes endothelial progenitor cells (EPCs), hematopoietic 
stem-progenitor cells, mesenchymal stem cells (MSCs) as well as myeloid cells151-
155. CACs are characterized by co-expression of specific receptors for angiogenic 
cytokines and progenitor cell markers. Because of the reduced expression of the 
angiogenic factors VEGF and SDF1 in ischemic tissue of HIF-1α+/- mice, recruitment 
and mobilization of CACs was found to be impaired150.  
In contrast to the well studied stimuli resulting in angiogenesis, stimuli able to trigger 
arteriogenesis are less well understood. Although arteriogenesis occurs in non-
hypoxic areas, it has been shown to occur concomitantly with angiogenesis after 
femoral arterial ligation156-158. In fact, proangiogenic myeloid cells need to pass 
through collateral remodelled blood vessels to reach the ischemic site. In addition, 
angiogenic factors like VEGF and PlGF were shown to be also arteriogenic159, 160. 
Vascular remodeling seems to be triggered by signals coming from ischemic tissues 
as well as from recruited bone marrow derived angiogenic cells (BMDAC). Current 
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knowledge suggests at least a partial overlap between signals triggering 
angiogenesis and signals inducing arteriogenesis, and there is increasing evidence 
for HIF-1 involvement in both processes145, 147, 149, 150, 161, 162.  
 
4.6.2 Effects of ageing and diabetes 
 
Critical limb ischemia (CLI) is a disease characterized by decreased tissue perfusion 
that causes pain, ulceration and gangrene eventually resulting in limb amputation163. 
Similarly to CLI patients, impaired recovery of limb perfusion after experimental 
arterial ligation was also observed in older mice and in HIF-1α+/- mice at all ages150, 
164. Impaired wound healing is a consequence of diabetes mellitus in humans and 
was also observed in a diabetes type 2 mouse model165. Hypoxia-induced 
stabilization of HIF-1α in mouse fibroblasts is impaired after exposure to high 
glucose. Moreover, HIF-1α protein levels were found to be lower in diabetic wounds 
compared to non-diabetic ulcers. Lower levels of HIF-1α and proangiogenic HIF 
target genes were observed in excisional wounds of diabetes type 2 mice. Also 
amount and mobilization of CACs were reduced in diabetic mice166-174. 
 
4.6.3 Pathophysiological effects of HIF-1  
 
High levels of HIF-1 were shown to be associated with highly vascularized and 
aggressive tumor phenotypes. Accordingly, loss of HIF-1 resulted in decreased 
tumor proliferation and angiogenesis144. Most cancer cells express high levels of 
VEGF and SDF1 due to HIF-1 upregulation as well as high mobilization and 
recruitment of CACs124, 175-178.  
In addition to their role in cancer, multiple proangiogenic HIF-1 target genes have 
been shown to be also implicated in retinal neovascularization, a pathological 
condition characterized by excessive blood vessel formation in the eye.  
These results support a role for HIF-1 in diseases characterized by impaired 
vascularization. 
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4.7 PHDs and angiogenesis 
 
In the last few years several studies addressed the question if prolyl-4-hydroxylases 
might be involved in angiogenesis by stabilizing HIF or even via HIF-independent 
pathways. First evidence was provided by the systemic application of prolyl-
hydroxylase inhibitors, which were shown to promote angiogenesis through 
stabilization of HIF in endothelial and epithelial cells. The use of different PHD-
inhibitors, namely L-mimosine (L-Mim), ethyl 3,4-dihydroxybenzoate (3,4-DHB), and 
6-chlor-3-hydroxychinolin-2-carbonic acid-N-carboxymethylamid (S956711) was 
shown to induce HIF-α protein and HIF-target gene expression in human and rodent 
cells. Moreover, HIF-α induction in rat kidneys was observed after systemic 
administration of L-Mim or S956711179. The use of the selective HIF-PHD-inhibitor 
PHI-1 was shown to induce HIF-1α and HIF-2α in a cell culture model of 
bronchopulmonary dysplasia (BPD), a disease characterized by insufficient alveolar 
and vascular development. The treatment was shown to enhance VEGF secretion 
as well as glucose consumption and not to be toxic for human lung cells180 . In a 
further study, the angiogenic phenotype of PHD1, PHD2 and PHD3 knock-out mice 
was evaluated. In Phd1 and Phd3 knock-out mice no visible angiogenic defects 
could be determined. In Phd2 knock-out mice, angiectasia, hyperactive 
angiogenesis and highly perfusable vessels were found. This angiogenic phenotype 
was independent of the local efficiency of PHD2 destruction in the single organs. 
Increased blood vessel density could be observed also in the brain, where the PHD2 
knock-out was very inefficient compared to other organs like liver, heart, kidney and 
lung. These results suggest that PHD2 but not PHD1 or PHD3 is a major negative 
regulator of vascular growth in adult mice81. PHD2 silencing by RNA-interference 
(RNAi) was shown to be sufficient to increase HIF transcriptional activity in NIH3T3 
cells181. Furthermore, in vivo angiogenesis could be observed in mice implanted with 
matrigel plugs containing NIH3T3 cells transfected with PHD2 short-interference 
(si)RNA constructs181. In a recent study, direct PHDs inhibition via short-hairpin 
(sh)RNA was shown to promote revascularization in a HIF-dependent manner in 
mice previously subjected to femoral artery ligation. These therapeutic 
revascularization was highest after PHD3 silencing, followed by PHD2 silencing, 
while lower proangiogenic activity was observed after PHD1 silencing182. Taken 
together, these data confirm a role for PHDs in modulating angiogenesis mainly by 
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stabilizing HIF expression and open new therapeutic possibilities for the treatment of 
ischemic diseases. 
 
4.8 The role of HIFs in cancer biology 
 
Solid human tumors usually present necrotic areas due to an insufficient blood 
supply. In addition to physical oxygen gradients within the tumor tissue, also 
temporal fluctuations in oxygen availability are common. Adaptation to the hypoxic 
tumor microenvironment promotes cancer progression, ultimately leading to 
death183-185.  
 
4.8.1 HIF-1α and HIF-2α levels in human cancers 
 
In the majority of solid human tumors, immunohistochemical studies have shown 
increased levels of both HIF-1α and HIF-2α in the cancerous tissue compared to the 
adjacent normal tissue186, 187. Different factors including intratumoral hypoxia, 
presence of ROS and activation of the mitogen-activated protein (MAP) kinase 
pathways are responsible for the increased HIF-1 levels. In addition, HIF-1α and 
HIF-2α  can be increased following genetic and epigenetic changes resulting in loss 
of function (LOF) of tumor suppressor genes or gain of function (GOF) of 
oncogenes. In cancer pathogenesis, cells with increased HIF activity seem to have a 
selective advantage188-191.  
 
4.8.2 Impact of HIF-1α and HIF-2α levels on cancer progression and 
mortality 
 
A large amount of data support an association between high levels of HIF-1α or HIF-
2α protein levels and increased patient mortality in many cancers. This relation is 
particularly well studied in breast cancer. A study involving 745 patients with invasive 
breast cancer showed that high HIF-1α levels correlated with poor overall survival as 
well as higher risk of metastasis formation192. A second study with 377 
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premenopausal breast cancer patients showed an impaired recurrence-free survival 
in lymph-node positive patients with high levels of HIF-1α 193. A third study evaluated 
132 patients with invasive breast carcinoma and again a positive significant 
correlation between HIF-1α and poor prognosis was found. In addition, also 
expression of the HIF- target gene carbonic anhydrase IX (CAIX) correlated in the 
same way, although being a weaker prognostic factor194. Similar conclusions were 
also drawn by Vleugel et al., who observed that perinecrotic HIF-1α overexpression 
accompanied by a strong induction of hypoxia-responsive genes like CAIX and 
glucose transporter 1 (GLUT1) associated with poor prognosis195. In a further study 
involving 171 breast cancer patients, increased HIF-1α correlated with shorter 
disease-free survival as well as overall survival196. Moreover, studies distinguishing 
between lymph-node positive or lymph node negative breast cancers, showed that 
HIF-1α is prognostic for an unfavourable outcome in both cases197, 198. Beside breast 
cancer, HIF-1α was also found to positively correlate with an aggressive colorectal 
carcinoma subtype, where its expression associated with increased 
metallothionein199. Interestingly, in a study involving 133 colorectal adenocarcinoma 
patients no correlation between clinical response and hypoxia markers, namely HIF-
1α, HIF-2α, GLUT1 and CAIX expressed in the tumor cells was found. Conversely, a 
correlation between HIF-2α, GLUT1 and CAIX expressed in the tumor-associated 
stroma was observed. Furthermore, stromal HIF-2α and CAIX were both significantly 
associated with a reduced overall survival200. In 75 patients suffering from advanced 
head and neck squamous cell carcinoma (HNSCC) and treated with carboplatin 
chemoradiotherapy both HIF-1α and HIF-2α expression were found to correlate with 
poor local relapse-free survival and poor overall survival201. In non-small cell lung 
cancer (NSCLC) HIF-2α was shown to have a negative impact on overall survival 
while HIF-1α only marginally correlated with poor outcome. Both isoforms were 
shown to associate with increased expression of various angiogenic factors202. HIF-
2α association with poor prognosis was also observed in malignant melanomas, 
where a high VEGF triggered angiogenic activity correlated with a limited 
inflammatory cell response203. Study of 58 PDAC patients showed significant 
correlation between HIF-1α and its target genes GLUT1 and VEGF with advanced 
tumor stage, lymph node metastasis and decreased overall survival204. In a recent 
study involving 90 patients suffering from rectal adenocarcinoma, HIF-1α but not 
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HIF-2α was found to correlate with a poor outcome205. A positive significant 
correlation between HIF-1α and VEGF levels with tumor grade, proliferation potential 
and vascular area was described in astrocytomas206. Taken together these studies 
suggest that HIF-α isoforms promote cancer progression and correlate with poor 
prognosis. However this conclusion is not absolute, as loss of HIF-2α was also 
shown to correlate with advanced tumor stage in immunohistochemical analysis of 
colon cancer biopsies207. Moreover, renal cell carcinoma xenografts suggest that 
HIF-1α GOF decreases xenograft growth208.  
 
4.9 PHDs and cancer 
 
The role of prolyl-4-hydroxylases in cancer is still not well understood. Recent 
studies classified them as tumor suppressor genes, but their expression levels as 
well as their prognostic relevance appears to be highly heterogeneous. Although 
correlation studies with all three isoforms of PHD can be found in the literature, most 
of the efforts were done in unraveling the role of PHD2 in carcinogenesis. PHD3 was 
proposed as a tumor suppressor gene in colorectal carcinoma, where its decreased 
expression was found to correlate with higher tumor grade and metastasis. PHD3 
seems to exert its tumor suppressor activity by inhibition of Iκκbeta phosphorylation 
and activation of NF-κB. Interestingly, this PHD3 effect was found to be independent 
of its hydroxylase function209. On the other hand, high nuclear expression of PHD1 
and PHD3 was shown to associate with poorer survival in pancreatic endocrine 
tumors. In the same study, increased PHD2 expression was found to correlate with 
higher aggressiveness, higher rate of recurrence and death. In addition, cytoplasmic 
expression of FIH was found to be increased in pancreatic endocrine tumors210. Also 
in HNSCC increased expression levels and nuclear translocation of PHD2 were 
shown to be associated with less differentiated, strongly proliferating and therefore 
highly aggressive tumors. Moreover, in some HNSCC tumors high PHD2 expression 
was not sufficient to downregulate HIF. In line with these findings, low nuclear PHD2 
expression in HNSCC was found to correlate with a positive outcome following 
radiation therapy211, 212. A complex model to correlate PHD2 levels with 
tumorigenesis was proposed by Lee et al. Their studies showed that in non-
tumorigenic fibroblasts, a small decrease in PHD2 levels, obtained via RNAi, led to 
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malignant transformation, whereas severe downregulation of the enzyme did not. In 
line with these results, overexpression of PHD2 in malignant fibroblasts was found to 
inhibit their tumorigenic potential. From these data a biphasic model for PHD2 tumor 
forming potential was proposed213. Loss of PHD2 was found to increase 
tumorigenesis also in a colon cancer model. Tumors derived from PHD2 
downregulated HCT116 cells were found to have a higher vessel density and to 
recruit more BMDCs. This PHD2 mediated angiogenic phenotype was found to be 
independent of HIF activity and PHD2 hydroxylation function. PHD2 downregulation 
was found to lead to angiogenin and interleukin-8 upregulation and this effect was 
shown to be NF-κB dependent214. In addition to studies investigating the role of 
PHD2 in tumor cells, recently also the effects of PHD2 levels in the surrounding 
environment particularly in endothelial cells, were considered. Analysis of the 
vasculature of tumors implanted in mice carrying a heterozygous PHD2 knock-out 
showed that in reduced PHD2 expression, vascular perfusion is improved due to 
vessel normalization and maturation. Interestingly, this normalization effect resulted 
in an inhibition of tumor invasion and metastasis215.  
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Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent
regulation of amphiregulin contributes to breast tumorigenesis
MR Bordoli1, DP Stiehl1, L Borsig1, G Kristiansen2, S Hausladen2, P Schraml2, RH Wenger1
and G Camenisch1
1Institute of Physiology and Zu¨rich Center for Integrative Human Physiology, University of Zu¨rich, Zu¨rich, Switzerland and
2Department of Pathology, University Hospital Zu¨rich, Zu¨rich, Switzerland
Hypoxia-elicited adaptations of tumor cells are essential
for tumor growth and cancer progression. Although ample
evidence exists for a positive correlation between hypoxia-
inducible factors (HIFs) and tumor formation, metastasis
and bad prognosis, the function of the HIF-a protein
stability regulating prolyl-4-hydroxylase domain enzyme
PHD2 in carcinogenesis is less well understood. In this
study, we demonstrate that downregulation of PHD2
leads to increased tumor growth in a hormone-dependent
mammary carcinoma mouse model. Tissue microarray
analysis of PHD2 protein expression in 281 clinical
samples of human breast cancer showed significantly
shorter survival times of patients with low-level PHD2
tumors over a period of 10 years. An angiogenesis-related
antibody array identified, amongst others, amphiregulin to
be increased in the absence of PHD2 and normalized after
PHD2 reconstitution. Cultivation of endothelial cells in
conditioned media derived from PHD2-downregulated
cells resulted in enhanced tube formation that was blocked
by the addition of neutralizing anti-amphiregulin anti-
bodies. Functionally, amphiregulin was regulated on the
transcriptional level specifically by HIF-2 but not HIF-1.
Our data suggest that PHD2/HIF-2/amphiregulin signal-
ing has a critical role in the regulation of breast tumor
progression and propose PHD2 as a potential tumor
suppressor in breast cancer.
Oncogene advance online publication, 20 September 2010;
doi:10.1038/onc.2010.433
Keywords: amphiregulin; hypoxia-inducible factors;
mammary carcinoma; prolyl-4-hydroxylases; tumor
vascularization
Introduction
Hypoxia is a characteristic feature of most solid tumors,
contributes to the malignant phenotype and is asso-
ciated with resistance to therapies and poor prognosis
(Brown and Wilson, 2004; Pouysse´gur et al., 2006).
Adaptive cellular responses to hypoxia are mainly
mediated by heterodimeric hypoxia-inducible transcrip-
tion factors (HIFs) and many HIF target genes are
involved in cancer progression (Wenger, 2002; Semenza,
2003; Wenger et al., 2005). On the molecular level,
HIF-a protein stability and transactivation activity are
regulated by oxygen-dependent hydroxylation of specific
prolyl and asparaginyl residues. The HIF prolyl-4-
hydroxylase domain proteins, PHD1, 2 and 3 are
responsible for normoxic HIF-a proteolysis. Prolyl-4-
hydroxylation is necessary for the interaction with the
von Hippel–Lindau tumor suppressor protein (pVHL)
that mediates HIF-a degradation (Maxwell et al., 1999;
Bruick and McKnight, 2001; Epstein et al., 2001;
Jaakkola et al., 2001; Ivan et al., 2002).
Although HIF-a overexpression is found in most human
cancers (Zhong et al., 1999) and correlates with poor
prognosis and resistance to treatment (Aebersold et al.,
2001), the role of PHDs in tumor formation remains
incompletely understood. Tumor suppressor functions have
been proposed for PHD1 as well as PHD3, whereas both
tumor promoting as well as suppressing effects have been
reported for PHD2. Ectopic expression of PHD1 in colon
carcinoma cells inhibited tumor growth and correlated with
increased necrosis and decreased microvessel density in a
mouse xenograft model (Erez et al., 2003). PHD3 was
found to be downregulated in colorectal cancer cells and
correlated with higher tumor grade and metastasis (Xue
et al., 2010) and loss of PHD3 was associated with the
development of pheochromocytomas by acting downstream
of c-Jun-mediated apoptosis (Lee et al., 2005). PHD2 has
been reported to induce senescence in endometrial cancer
cells by regulating HIF-mediated signal transduction path-
ways (Kato et al., 2006). On the other hand, increased
expression levels of PHD2 have been shown to be
associated with an aggressive phenotype in head and neck
squamous cell carcinoma (Jokilehto et al., 2006). Over-
expression of all three PHDs and the asparaginyl hydro-
xylase factor inhibiting HIF correlated with tumor
aggressiveness and higher rate of recurrence in pancreatic
endocrine tumors (Couvelard et al., 2008). In addition, a
biphasic model for the relationship between PHD2 and
tumor-forming potential has been suggested: small de-
creases of PHD2 led to malignant transformation ofReceived 18 March 2010; revised 16 July 2010; accepted 13 August 2010
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non-tumorigenic fibroblasts, whereas strongly decreased
PHD2 levels did not (Lee et al., 2008). In summary, the
function of PHDs in cancer remains incompletely under-
stood. Current data suggest that they can be functionally
inactivated, genetically mutated and epigenetically down-
regulated in cancer and additional tissue-specific factors
might impinge on PHD regulation.
In this study, we have studied the function of PHD2
in a mammary carcinoma model and demonstrate
that PHD2 downregulation promotes tumor growth.
In clinical samples, low-PHD2 protein expression levels
correlated significantly with shorter survival times of
breast cancer patients. We confirmed PHD2-dependent
vascular endothelial growth factor (VEGF) and inter-
leukin-8 (IL-8) modulation and identified amphiregulin
to be induced by loss of PHD2 and normalized by
PHD2 reconstitution, suggesting that amphiregulin
contributes to breast cancer progression.
Results
Increased tumor progression by PHD2 downregulation
To investigate the role of PHD2 in tumor development,
stable PHD2 knockdown clones and non-targeting
control clones were generated in human breast carcinoma
MCF-7 cells by short hairpin RNA (shRNA) inter-
ference. After selection, stable shPHD2 clones C1 and
B1 were further analyzed by reverse transcriptase
quantitative PCR (RT–qPCR). Both clones showed
efficient PHD2 mRNA downregulation under normoxic
as well as prolonged hypoxic conditions (Figure 1a),
whereas PHD1 and PHD3 mRNA levels were not
significantly altered (data not shown). HIF-1a, HIF-2a
and ARNT mRNA levels slightly varied under the
conditions analyzed, but were not significantly affected
by PHD2 downregulation (Figure 1a). Parental MCF-7
and control shRNA-transfected cells differed neither on
the PHD2 mRNA (Figure 1a) or protein (Supplemen-
tary Figure S1) level, nor in proliferation or morphology
(data not shown). Thus, both cell lines were subseq-
uently used as controls. Immunoblot analysis confirmed
efficient PHD2 knockdown in C1 and B1 clones also
under prolonged hypoxic, that is, PHD2 inducing
conditions (Figure 1b). Stabilization of normoxic HIF-
1a and increased hypoxic accumulation of HIF-2a
protein was observed in PHD2-downregulated MCF-7
cells (Figures 1b and 2b, respectively). In clone C9, the
less efficient downregulation of PHD2 correlated with
reduced normoxic HIF-1a stabilization when compared
with the clones C1 and B1 (Figure 1b). Normoxic HIFa
protein accumulation in shPHD2 cells is less pro-
nounced than in hypoxic control cells, indicating that
additional factors might contribute to the normoxic
regulation of HIF-a subunits in MCF-7 cells.
To analyze the function of PHD2 in tumor formation
in vivo, athymic nude mice were subcutaneously injected
with parental and PHD2 knockdown MCF-7 cells.
Because MCF-7 proliferation is estrogen dependent
(Supplementary Figure S2), estrogen-releasing pellets
were subcutaneously implanted into mice before the
injection of MCF-7 cells. Tumor growth of PHD2-
downregulated MCF-7 cells in vivo was significantly
increased when compared with control cells (Figure 1c,
left panel). Importantly, differences in tumor growth
were independent of unequal intrinsic proliferation
potentials, as parental and shPHD2 MCF-7 cells
showed comparable growth rates and viability in vitro
(Figure 1c, right panel). Tumor growth was analyzed
over a time period of 60 days. Thereafter, sustained
in vivo PHD2 suppression was confirmed on the mRNA
as well as on the protein levels (Supplementary Figure
S3). Recently, it has been proposed that heterozygous
endothelial Phd2 deficiency stabilizes tumor vasculature
and inhibits metastasis (Mazzone et al., 2009). Although
tumors in our model were wild type for Phd2 in host-
derived endothelial cells, we did not observe metastasis
in mice subcutaneously injected with shPHD2 cells.
Because MCF-7 are poorly invasive breast cancer cells,
we injected these cells also intravenously but still
detected no incidence of metastasis, even by RT–qPCR
analysis of lung samples using human PHD2-specific
primers (data not shown).
Analysis of PHD2 protein expression using a tissue
micro array (TMA) of 281 human breast cancer patient
samples showed predominantly a diffuse and fairly
homogenous cytoplasmic immunoreactivity in invasive
breast cancer cells and no membraneous staining. Low
or very high PHD2 levels were observed in 82 and 199
cases, respectively (Figure 1d, left panel). Apart from a
significant association of low PHD2 levels with a
postmenopausal status, no other associations with clinico-
pathological parameters were found (Supplementary
Table 1). Univariate survival analysis by the Kaplan–
Meier method showed significantly shorter survival times
of patients with tumors having low PHD2 levels (10 years
survival rates: 52 vs 67%, P¼ 0.026; Figure 1d, right
panel). In a probatory multivariate Cox analysis (includ-
ing tumor grades pT, pN, G) of estrogen receptor and
PHD2, PHD2 failed to demonstrate independent prog-
nostic significance (data not shown). To confirm the
specificity of the anti-PHD2 antibody, parental MCF-7
and shPHD2 C1 cells were pelleted and embedded in
paraffin for immunohistochemical detection of PHD2
protein expression using the same conditions as for the
TMA experiments (Supplementary Figure S4).
Figure 1 PHD2 downregulation promotes tumor progression. (a) Transcript levels of PHD2, HIF-1a, HIF-2a and ARNT were
analyzed in parental, control shRNA and shPHD2 MCF-7 cells by RT–qPCR. Cells were exposed to hypoxia (1% O2) for up to 72 h.
(b) Protein levels of HIF-1a, PHD2 and PHD3 were determined by immunoblotting. (c) Parental and shPHD2 MCF-7 cells were
subcutaneously injected into nude mice and tumor growth measured over 60 days starting from a minimal tumor diameter of 5mm
(left panel). In vitro cell proliferation of parental and shPHD2 MCF-7 cells was assessed by counting cells over 10 days (right panel).
(d) Examples from mammary carcinoma TMA immunostaining for PHD2 (left panel) and ten years survival analysis by Kaplan–Meier
plotting (right panel). *Po0.05, **Po0.01, ***Po0.001, C1 vs parental; #Po0.05, ##Po0.01, B1 vs parental.
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Overexpression of PHD2 in shPHD2 cells suppresses
tumor growth
To exclude that shRNA off-target effects increased the
tumor growth in shPHD2 MCF-7 clones, we reconsti-
tuted the expression of PHD2 in the stable shPHD2
clone C1. Immunoblot analysis showed constitutively
elevated PHD2 protein levels under normoxic as well as
hypoxic conditions in the selected reconstituted clones
no. 1 and no. 2 (Figure 2a). PHD2 reconstitution also
reduced normoxic HIF-1a protein levels and attenuated
hypoxic HIF-2a accumulation (Figure 2b). Although
PHD2 expression was higher in both reconstituted
clones than in parental MCF-7 cells, no difference in
in vitro proliferation rates and viability was observed
(data not shown). Implantation of PHD2-reconstituted
and parental MCF-7 cells into athymic nude mice
resulted in tumors in 13.6 and 77.3% of all cases,
respectively. In addition, the three successfully grown
tumors of PHD2-reconstituted cells showed a signifi-
cantly decreased volume compared with tumors derived
from parental MCF-7 cells (Figure 2c). Subsequent
tumor tissue analysis confirmed increased PHD2 expres-
sion in reconstituted compared with parental cells,
suggesting that PHD2 overexpression leads to suppres-
sion of tumor growth (Figure 2d).
PHD2 suppression increases tumor angiogenesis
and modulates secreted angiogenic factors
Tumor vascularization of experimental tumors derived
from parental and shPHD2 MCF-7 cells was analyzed
by PECAM-1 immunostaining. Knockdown of PHD2
resulted in a more elaborated and denser vascular
network (Figure 3a). Quantitative analysis revealed a
significant increase in vessel density, area and diameter
in shPHD2 compared with parental cells (Figure 3b).
Tumors derived from parental or shPHD2 MCF-7 cells
showed no obvious morphological differences by
hematoxylin/eosin staining (data not shown).
To investigate a possible regulation of secreted
angiogenic factors by altered PHD2 levels, we incubated
human angiogenesis arrays with conditioned media of
parental, shPHD2 or reconstituted PHD2 MCF-7 cells.
To eliminate potential clonal differences between
maternal and shPHD2 cell lines, we also used pools of
lentivirally transduced shPHD2 MCF-7 cells (Supple-
mentary Figure S5). Compared with conditioned media
of parental MCF-7 and reconstituted PHD2 cells,
VEGF was increased in shPHD2 cells, suggesting
activation of the HIF pathway (Supplementary Figure
S6). In addition, IL-8 as well as amphiregulin was
elevated in the absence of PHD2, whereas reduced in
Figure 2 Tumor growth is repressed by PHD2 overexpression. (a) MCF-7 shPHD2 cells were transfected with a V5-tagged PHD2
expression vector and PHD2 protein levels determined by immunoblotting. (b) Protein levels of HIF-1a and HIF-2a were determined
by immunoblotting. (c, d) Parental, shPHD2 C1 and PHD2-reconstituted MCF-7 cells (clone no. 2) were subcutaneously injected
into nude mice and tumor volume (c) as well as PHD2 mRNA levels (d) determined at the end of the experiment after 60 days.
Rec., reconstituted, Rel., relative. *Po0.05, **Po0.01, ***Po0.001.
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cells overexpressing PHD2 when compared with par-
ental MCF-7 cells. Recently, IL-8 has been shown to be
induced by PHD2 downregulation in a HIF-indepen-
dent but nuclear factor-kB (NF-kB)-dependent manner
(Chan et al., 2009), confirming the relevance of our
experimental approach. However, amphiregulin induc-
tion by PHD2 downregulation has not been described
previously.
Other pro-angiogenic factors abundantly secreted by
MCF-7 cells include insulin-like growth factor binding
protein 2, matrix metallopeptidase 9 and tissue inhibitor
of metalloproteinase 1. However, secretion of these
factors was independent of PHD2 (Supplementary
Figure S6).
PHD2 regulates amphiregulin-dependent tube formation
in vitro
To elaborate the PHD2-dependent function of amphir-
egulin in more detail, we performed tube formation
assays in vitro. Incubation of HUVEC cells with
supernatant of parental MCF-7 cells resulted in
moderate tube formation (Figure 3c). In contrast, after
PHD2 downregulation tube formation was significantly
increased as determined by counting branch points and
estimating total tube network length. Conversely, tube
formation was markedly decreased by shRNA-mediated
downregulation of amphiregulin gene expression
(Figure 3c), already following amphiregulin transcript
level repression by only approximately 50% (Supple-
mentary Figure S7). Importantly, stimulation of
tube formation by supernatants of shPHD2 MCF-7
cells was significantly reduced by pre-incubation with a
neutralizing anti-amphiregulin antibody (Figure 3d),
suggesting that the PHD2-mediated increase in tube
formation was at least partly mediated by amphiregulin
secretion.
Amphiregulin transcription is regulated by PHD2
Analysis of amphiregulin mRNA levels in MCF-7 cells
by RT–qPCR demonstrated increased amphiregulin
transcript levels after PHD2 suppression and reduced
amphiregulin mRNA levels after PHD2 overexpression
(Figure 4a). Transfection of a firefly luciferase reporter
gene driven by the amphiregulin gene (AREG) promoter
(pAREG) into parental, shPHD2 or reconstituted
MCF-7 cells resulted in relative luciferase activities
recapitulating the regulation of the endogenous amphir-
egulin transcript levels in these cell lines (Figure 4b).
In contrast to the known hypoxia-inducible gene
carbonic anhydrase 9 (CA9), amphiregulin mRNA
levels were not induced under hypoxic conditions
(Figure 4c), indicating that amphiregulin regulation
might be independent of the prolyl-4-hydroxylase
enzymatic function of PHD2. Moreover, pharmacologic
inhibition of PHD hydroxylase function using the pan-
PHD inhibitor DMOG, did not induce amphiregulin
expression, whereas CA9 and PHD2 were increased as
expected (Supplementary Figure S8).
To analyze the function of PHD2 on amphiregulin
transcription in more detail, we transfected shPHD2
MCF-7 cells with pAREG reporter plasmids (depicted
in Figure 4d) together with active (PHD2) or inactive
hydroxylase mutant PHD2. All pAREG reporter
plasmids were similarly responsive to PHD2 coexpres-
sion, irrespective of the presence of the putative HIF-
binding site and functional PHD2 hydroxylase activity
(Figure 4e, left panel). As expected, the HIF-dependent
reporter plasmid pH3SVL (Wanner et al., 2000)
responded to wild type but not mutant PHD2. Hypoxic
exposure only marginally induced pAREG reporter
activity and the repressive effect of PHD2 coexpression
was preserved at reduced oxygen concentration
(Figure 4e, right panel). Note that pH3SVL was strongly
induced by hypoxia and PHD2 reconstitution less
efficiently reduced pH3SVL reporter activity under
hypoxic than normoxic conditions. In conclusion, these
data are all consistent with the notion that PHD2
represses amphiregulin transcription in a hydroxylase-
independent manner.
Cyclic AMP response element (CRE)-binding pro-
tein-dependent regulation of amphiregulin gene expres-
sion has been reported in the intestinal epithelial cells
and a functional CRE has been identified in the human
amphiregulin promoter (Plowman et al., 1990; Lee et al.,
1999; O’Reilly et al., 2006). To delineate the function
of CRE-binding protein in PHD2-dependent pAREG
regulation, we cotransfected shPHD2 MCF-7 cells with
wild-type or mutant CRE pAREG reporter plasmids
together with active or mutant PHD2. Although
pAREG reporter activity was reduced on CRE site
mutation, the wild-type and mutant PHD2 repressive
effect were preserved (Figure 4f, left panel). The HIF-
dependent reporter plasmid pH3SVL was again used as
control (Figure 4f, right panel).
Whereas functional NF-kB-binding sites in the
angiogenin as well as IL-8 promoters have been reported
to be required for tumor necrosis factor-a-mediated
induction of reporter gene expression (Chan et al.,
2009), amphiregulin mRNA levels were neither induced
by tumor necrosis factor-a treatment (Supplementary
Figure S9) nor suppressed by small interfering RNA
(siRNA)-mediated downregulation of the NF-kB sub-
unit RelA (Supplementary Figure S10). These data
suggest that the signaling pathway involved in the
PHD2-dependent control of amphiregulin expression in
mammary carcinoma cells is different from the signaling
pathway reported for PHD2- and NF-kB-dependent
regulation of angiogenin and IL-8 in colon carcinoma
cells (Chan et al., 2009).
HIF-2a-specific regulation of amphiregulin gene
expression
Downregulation of PHD2 in MCF-7 cells resulted
in a slight normoxic accumulation of both HIF-1a and
HIF-2a protein levels (Figure 5a). Even though amphir-
egulin transcriptional regulation was independent of
PHD2 hydroxylase function, we hence investigated
whether amphiregulin expression might additionally be
regulated in a HIF-a isoform-specific manner. There-
fore, stable shHIF-1a and shHIF-2a MCF-7 pool of
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clones were generated (Figure 5b, left panel) and
analyzed for amphiregulin gene expression by RT–
qPCR (Figure 5b, right panel). Compared with parental
cells, transcript levels of amphiregulin were upregulated
in shHIF-1a and decreased in shHIF-2a MCF-7
cells, indicating that HIF-2a is mainly responsible
for the regulation of amphiregulin gene expression.
As evidenced by immunoblot analysis (Figure 5b, left
panel), increased amphiregulin mRNA levels in shHIF-
1a cells might probably be due to higher HIF-2a levels
in these cells. Conversely, overexpression of HIF-2a in
parental MCF-7 cells increased amphiregulin promoter-
dependent reporter gene activity, whereas exogenous
expression of HIF-1a had no effect (Figure 5c, left panel).
Figure 4 PHD2-dependent transcriptional regulation of amphiregulin. (a) Amphiregulin mRNA levels of parental, shPHD2 and
PHD2-reconstituted MCF-7 cells were measured by RT–qPCR. (b) The amphiregulin promoter-driven firefly luciferase reporter gene
construct pAREG(640/þ 120) was transfected into parental, shPHD2 and PHD2-reconstituted MCF-7 cells and relative luciferase
activities were quantified. (c) Amphiregulin and CA9 mRNA levels were measured by RT–qPCR in MCF-7 cells cultured under
normoxic (20% O2) or hypoxic (1% O2) conditions for up to 72 h. (d) Schematic representation of the reporter gene constructs driven
by the human AREG promoter. 50-Regulatory elements are labeled relative to the transcriptional start site (TSS). Two putative
consensus HIF binding sites (HBS) are indicated in capital letters. (e) A measure of 200 ng pAREG reporter constructs as indicated
were cotransfected with either 800 ng wild-type PHD2 or a hydroxylase-deficient PHD2 mutant (mtPHD2), and relative luciferase
activities were quantified. The HIF-dependent reporter plasmid pH3SVL served as control. (f) The indicated plasmids were
cotransfected as mentioned above (e). dep., dependent; Rec., reconstituted, Rel., relative. *Po0.05, **Po0.01.
Figure 3 Tumor angiogenesis is enhanced by PHD2 suppression and subsequent amphiregulin upregulation. (a) PECAM-1 staining
of cryosections derived from parental and shPHD2 MCF-7 tumors. (b) Quantification of vessel number, area and diameter.
(c) HUVEC cells were resuspended in supernatants of parental, shPHD2 or shAREG MCF-7 cells and plated on matrigel-coated
slides. Tube formation was quantified by estimating the number of branching points and overall length of the network. (d) HUVEC
cells were resuspended in supernatants of shPHD2 cells containing a neutralizing antibody against amphiregulin and the branching
points were counted. DAPI, 40,6-diamidino-2-phenylindole, PECAM-1, platelet/endothelial cell adhesion molecule 1. *Po0.05,
**Po0.01, ***Po0.001.
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A PHD2 promoter-driven, that is, HIF-dependent,
reporter plasmid was used to control for efficient
HIF-1a and HIF-2a expression (Figure 5c, right panel).
To analyze the function of HIF-2 in amphiregulin
promoter regulation, we used again the pAREG repo-
rter constructs depicted in Figure 4d and cotransfected
them into MCF-7 shHIF-2a cells together with either
HIF-2a or an empty expression vector. All pAREG
reporter plasmids were induced by exogenous HIF-2a
expression, irrespective of the presence of the putative
HIF-binding site (Figure 5d). The promoter-less repor-
ter backbone pGL2 served as negative control.
Figure 5 Amphiregulin transcription is regulated by HIF-2. (a) Protein levels of PHD2, HIF-1a and HIF-2a were determined by
immunoblotting in parental and shPHD2 (clone C1) MCF-7 cells cultured under normoxic or hypoxic conditions. (b) Nuclear HIF-1a
and HIF-2a protein levels were determined by immunoblotting (left panel) and amphiregulin mRNA levels were measured in parental,
shHIF-1a and shHIF-2a MCF-7 cells (right panel). (c) MCF-7 parental cells were cotransfected with the amphiregulin promoter
construct pAREG(640/þ 120) together with either an empty, HIF-1a or HIF-2a expression vector. Cells were cultured under
normoxic or hypoxic conditions for 24 h and relative luciferase activities quantified. A PHD2 promoter-driven reporter plasmid was
used as a control. (d) MCF-7 shHIF-2a cells were cotransfected with 200 ng pAREG reporter construct as indicated together with
either 800 ng HIF-2a or empty expression vector, and cultured under normoxic conditions. Promoterless pGL2basic served as negative
control. Transcript levels of HIF-1a, HIF-2a, amphiregulin and CA9 were analyzed in shPHD2/shHIF-1a (e) and shPHD2/siHIF-2a
(f) MCF-7 cells by RT–qPCR. dep., dependent; Rel., relative.
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Finally, either HIF-1a or HIF-2a was downregulated
in shPHD2 MCF-7 cells and endogenous gene expres-
sion was analyzed by RT–qPCR. HIF-1a suppression
upregulated amphiregulin mRNA levels (Figure 5e),
probably indirectly because of elevated HIF-2a gene
expression as previously observed on the protein level
in stable HIF-1a knockdown cell pools (Figure 5b).
In contrast, HIF-2a suppression downregulated amphi-
regulin mRNA levels and did not influence HIF-1a
gene expression (Figure 5f). CA9 served as positive
control and seems to be a HIF-1-specific target gene.
In conclusion, these data indicate that amphiregulin
transcription is regulated by HIF-2 independent of the
putative HIF-binding site in the promoter region.
Discussion
Although the role of HIFs in tumor formation and
metastasis is well known, the function of regulators of
HIF-a stability during neoplastic growth has come into
focus only recently. We report in this study that PHD2
functions as a tumor suppressor in xenografted tumors
derived from breast carcinoma MCF-7 cells and clinical
data indicate that high PHD2 protein levels are a
positive prognostic survival factor in human mammary
carcinomas. Mechanistically, amphiregulin contributed
to PHD2 regulated in vitro tube formation and amphi-
regulin transcription was increased specifically by HIF-2
in breast carcinoma MCF-7 cells.
During progression of our analysis, RNA interfer-
ence-mediated downregulation of PHD2 has recently
been used to further elucidate the function of PHD2 in
tumor formation. Wu et al. (2008) observed elevated
in vivo angiogenesis of tumors derived from PHD2-
silenced NIH3T3 cells and this phenotype was attributed
to HIF-mediated increased expression of the pro-angio-
genic VEGF and fibroblast growth factor-2. Evidence
for a tumor suppressive function of PHD2 has recently
also been reported by Chan et al. (2009). PHD2 down-
regulation increased normoxic NF-kB activity, leading
to a HIF-independent elevated secretion of the pro-
angiogenic factors IL-8 and angiogenin in a colon
carcinoma cell model. Immunohistochemical analysis of
PHD2 protein levels in human breast cancer samples
showed that 6 out of 11 patient samples had higher
levels of PHD2 in normal tissue than in matched tumor
samples (Chan et al., 2009). Our analysis of ten years
survival rates from 281 clinical mammary carcinoma
samples revealed significantly enhanced survival times of
patients having tumors with high PHD2 levels, support-
ing the proposed tumor suppressing role of PHD2.
Although high PHD2 transcript levels have been
reported in estrogen receptor-negative and human
epidermal growth factor receptor-2 (HER2)-negative
breast carcinoma (Zhang et al., 2009), we found a signi-
ficant association of low PHD2 levels with a postmeno-
pausal state but not with tumor grades, estrogen
receptor, progesteron receptor or HER2. Clinicopatho-
logical data from our cohort were collected before
the broad introduction of aromatase inhibitors for
postmenopausal women, but association of PHD2
with postmenopausal state might still be explained by
estrogen receptor status alteration, because PHD2
correlated with fatty acid synthase, another marker of
postmenopausal status. In tumor angiogenesis, PHD2
levels have to be considered not only in cancer cells
but also in stromal cells. Indeed, endothelial PHD2
levels have been reported to dramatically affect tumor
growth by influencing intratumoral vessel develop-
ment (Mazzone et al., 2009). In summary, accumulating
evidence suggests an important regulatory role of PHD2
in tumor angiogenesis.
Amphiregulin is a heparin-binding glycoprotein that
has originally been isolated from conditioned media of
human breast carcinoma MCF-7 cells and identified as
epidermal growth factor receptor ligand (Shoyab et al.,
1988). During development, amphiregulin is the most
abundant epidermal growth factor-like growth factor in
the pubertal mammary gland and has an important role
in ductal morphogenesis (Luetteke et al., 1999). There is
clear evidence for a role of amphiregulin in breast cancer
initiation as well as progression (McBryan et al., 2008;
Willmarth and Ethier, 2008). Amphiregulin is often
overexpressed in mammary carcinoma (Qi et al., 1994)
and generally higher in invasive breast carcinomas than
in normal mammary epithelium (Panico et al., 1996).
Importantly, amphiregulin antisense expression in a
transformed human breast epithelial cell line that has
been selected for its increased tumorigenicity in vivo,
reversed the malignant phenotype in nude mice and led
to a significant reduction in tumor mass (Ma et al.,
1999). Moreover, tumor vascularization was markedly
reduced in tumors derived from amphiregulin antisense
expressing cells, suggesting that amphiregulin modulates
angiogenesis in these cells. Although it remains largely
unknown how amphiregulin might mechanistically
contribute to breast cancer pathogenesis in general,
regarding angiogenesis it has been shown that amphir-
egulin antisense expression reduced the angiogenic
factor TGFb1 (Giusti et al., 2003) and upregulated the
expression of IL-8 in human airway epithelial cells
(Chokki et al., 2006). Our results showed that the in vitro
tube formation potential of shPHD2 cells was sign-
ficantly increased compared with parental MCF-7 cells
and again reduced after addition of neutralizing anti-
amphiregulin antibodies, although elevated levels of the
potent angiogenic factors VEGF and IL-8 remained
unchanged. This suggests that amphiregulin contributes
substantially to pro-angiogenic modulation by MCF-7
breast cancer cells.
A few regulators of amphiregulin gene expression
have been reported previously: EGF-related growth
factors auto- and cross-induce each other (Barnard
et al., 1994), and amphiregulin transcription is induced
by estrogen, probably indirectly as no estrogen-response
elements have been identified in the amphiregulin
promoter region (Martinez-Lacaci et al., 1995). In fetal
kidney differentiation, the zinc-finger transcription
factor Wilms tumor suppressor (WT1) has been shown
to regulate amphiregulin gene expression (Lee et al.,
1999), but we did not find any WT1 expression in
PHD2- and HIF-2-dependent regulation of amphiregulin
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MCF-7 cells (data not shown). Recently, BRCA1 has
been described as transcriptional repressor of amphir-
egulin and loss of BRCA1 resulted in elevated amphir-
egulin protein levels (Lamber et al., 2010). The role of
oxygen in amphiregulin regulation is incompletely
understood. Whereas hyperoxia induced amphiregulin
in a model of bronchopulmonary dysplasia (Wagenaar
et al., 2004), hypoxia has been reported to upregulate
amphiregulin gene expression in a CRE-binding protein-
dependent manner in intestinal epithelial cells (O’Reilly
et al., 2006).
Our results suggest that PHD2 regulates amphiregulin
on the transcriptional level, directly or indirectly invol-
ving HIF-2 but not HIF-1 (a schematic overview is
shown in Supplementary Figure S11). Intriguingly,
although HIF-2 clearly increased endogenous amphir-
egulin mRNA levels and exogenous amphiregulin
promoter activity, cultivation of MCF-7 cells under
hypoxic conditions did not significantly regulate endo-
genous amphiregulin transcript levels or promoter
activity. These data suggest that normoxic, basal
HIF-2 levels are sufficient for amphiregulin gene
expression which is not further induced by hypoxic
stabilization of HIF-2a. Supporting this hypothesis, it
has been shown that HIF-2 is slightly more abundant in
normoxic and mildly hypoxic cells than HIF-1 (Wies-
ener et al., 1998) and a recent report demonstrated that
the HIF-2-specific target gene, CITED2, was maximally
expressed under normoxic conditions (Franovic et al.,
2009). Furthermore, it has been shown that the vascular
endothelial–cadherin gene is not regulated by hypoxic
conditions, but the vascular endothelial–cadherin pro-
moter is nevertheless activated by HIF-2 together with
the Ets-1 transcription factor (Le Bras et al., 2007).
Several groups reported on the role of PHDs in
regulating in vivo angiogenesis. Conditional knockout
of PHD2, but not PHD1 or PHD3, resulted in increased
secretion of VEGF and enhanced angiogenesis (Takeda
et al., 2007) and application of pan-PHD inhibitors in
rats led to HIF-a stabilization and stimulated angio-
genesis (Warnecke et al., 2003). As PHD inhibitors have
been developed to treat ischemic diseases, concerns
might arise about adverse effects of these inhibitors in
tumor progression. Our study demonstrates that PHD2
has a critical role in tumor progression, suggesting that a
combinatory treatment regimen of PHD inhibitors
together with antiangiogenic compounds or, if available,
anti-HIF-a isoform-specific inhibitors, might be re-
quired to avoid the induction of potentially tumor
promoting signaling pathways.
Materials and methods
Plasmids
Cloning of PHD2 expression vectors and other plasmids was
carried out using Gateway technology (Invitrogen, Basel,
Switzerland) as described previously (Barth et al., 2007).
Cell culture and transfections
Human MCF-7 breast carcinoma cells were cultured in high-
glucose Dulbecco’s modified Eagle’s medium (Sigma, Buchs,
Switzerland) as described previously (Camenisch et al., 1999).
HUVEC cells were kindly provided by TF Lu¨scher (Zu¨rich,
Switzerland) and cultured in complete endothelial basal
medium-2 containing 2% fetal calf serum (Lonza, Basel,
Switzerland). For long-term hypoxia, cells were grown in a
gas-controlled glove box (InvivO2 400, Ruskinn Technologies,
Leeds, UK). Transfections were performed using polyethyle-
nimine (Polysciences, Warrington, PA, USA) as described
previously (Stiehl et al., 2006).
Immunoblotting
Immunoblot analyses were performed as previously
described (Balamurugan et al., 2009). Antibodies used were
mouse monoclonal antibody (mAb) anti-HIF-1a (Transduc-
tion Laboratories, BD Biosciences, Allschwil, Switzerland),
anti-HIF-2a (Novus Biologicals, LuBioScience, Lucerne,
Switzerland), mAb anti-V5 (Invitrogen), mAb anti-b-actin
(Sigma), rabbit polyclonal anti-PHD2 antibody (Novus),
mAb anti-PHD3 was kindly provided by PJ Ratcliffe
(Oxford, UK).
Reporter gene assays
Construction of the HIF-dependent firefly luciferase reporter
gene construct pH3SVL was described previously (Wanner
et al., 2000). The amphiregulin promoter plasmid pAREG
(641/þ 120) was kindly provided by SB Lee (Bethesda, USA)
(Lee et al., 1999). Truncations of this plasmid have
been constructed by PCR and recombinant cloning techniques.
As sequencing revealed point mutations in the parental
plasmid, the (120/þ 120) region was de novo cloned
from MCF-7 genomic DNA. The consensus CRE site
(50-TGACGTC-30) in pAREG(120/þ 120), located 65
nucleotides upstream of the transcriptional start site, was
mutated to (50-TGAaaTC-30) by site-directed mutagenesis.
The PHD2 luciferase reporter plasmid pP2P(603/þ 3)wt is a
truncated version of the previously published human PHD2
promoter (Metzen et al., 2005). Cells were cotransfected
with 200 ng reporter plasmid and 10 ng pRLSV40 Renilla
luciferase reporter vector (Promega, Du¨bendorf, Switzerland)
and luciferase reporter gene activity was determined using
the dual-luciferase reporter assay system according to the
manufacturer’s instructions (Promega).
mRNA quantification
Total cellular RNA was extracted as described previously
(Barth et al., 2007). First-strand complementary DNA
synthesis was performed with 1–5 mg total RNA using reverse
transcriptase and mRNA levels were measured by real-time
quantitativePCR using a SybrGreen qPCR reagent kit (Sigma)
in combination with the MX3000P light cycler (Stratagene,
Amsterdam, The Netherlands). To verify RNA integrity and
equal input levels, ribosomal protein L28 mRNA was
determined, and the data were expressed as ratios relative to
L28 levels.
Mice xenografts
Estrogen-releasing pellets (0.72mg 17b-estradiol 60-days
release, Innovative Research of America, Sarasota, FL,
USA) were subcutaneously implanted into the neck of NMRI
female nude mice (Harlan Europe, The Netherlands) 5 days
before subcutaneous injection of 1–2 107 MCF-7 cells in
200 ml phosphate-buffered saline. Tumors were measured using
a caliper every 3 days. Animal experimentation was approved
by the veterinary office of the Kanton Zu¨rich (approval
number 04/2008).
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Tissue specimen and TMA analysis
For immunohistochemistry, our study included TMAs of 281
invasive breast cancer cases diagnosed at the Institute of
Surgical Pathology (University Hospital, Zu¨rich, Switzerland)
as described (Theurillat et al., 2007). Tumor histology was
determined according to the criteria of the World Health
Organization (2003), whereas disease stage was assessed
according to the International Union Against Cancer (UICC,
2002). Tumors were graded according to Bloom and Richard-
son, as modified by Elston and Ellis (1993) The clinicopatho-
logical characteristics of the patients/tumors are described in
Supplementary Table 1. Patient age at the time of diagnosis
ranged from 26 to 98 years with a median of 61 years (mean
62). For statistical analysis, only cases with clinical follow-up
data were considered. The median observation time for overall
survival was 61 months for patients still alive at the time
of analysis. In all, 74 patients (27%) died during follow-up.
Data on adjuvant therapy was not available. PHD2 expression
was semiquantitatively scored as low or high.
Statistical analysis
Where not otherwise indicated, results are presented as mean
values±standard error of the mean of at least n¼ 3
independent experiments. P-values were obtained by unpaired
t-tests (*Po0.05, **Po0.01, ***Po0.001). For statistical
TMA analysis, PHD2 expression data were analyzed in
crosstables with w2-test. Survival analysis was conducted
according to Kaplan–Meier with log rank test and multivariate
Cox regression analysis (inclusion model). All statistics were
calculated using PASW (SPSS 18) software.
Immunohistochemistry
Dissected tumors were macroscopically evaluated, cut in half,
and frozen in embedding medium (Tissue-Tek OCT com-
pound, Sakura Finetek, Staufen, Germany). Acetone-fixed
cryosections (8 mm) were blocked with 0.5% bovine serum
albumin and incubated with anti-PECAM-1 antibody (BD
Biosciences) for 1 h at room temperature to stain blood vessels.
Tumor sections were further incubated with Alexa 568-
conjugated goat anti-rat antibodies (Invitrogen) followed by
nuclear staining with 4,6-diamidino-2-phenylindole and
mounting in Prolong medium (Invitrogen). Blood vessel
density, area and size were quantified using Axio Vision
software (Carl Zeiss, Feldbach, Switzerland). TMA sections
were processed using an automated immunohistochemistry
platform (Benchmark, Ventana, Roche, Illkirch, France) with
a PHD2 polyclonal anti-PHD2 antibody at 1:100 dilution
(NB100-137; Novus Biologicals).
shRNA constructs and lentiviral infections
Expression vectors encoding shRNA sequences targeting
human PHD2, HIF-1a, HIF-2a and amphiregulin driven by
the U6 promoter in a pLKO.1-puro plasmid were purchased
from Sigma. Variants of shRNA expression plasmids bearing a
hygromycin resistance marker were generated by replacing the
original puromycin resistance cassette in pLKO.1. Viral
particles were produced in HEK293T cells using the Vira-
Power lentiviral expression system according to the manufac-
turer’s instructions (Invitrogen).
RNA interference
MCF-7 cells were transfected with 100 nM siRNA duplex
oligonucleotides using Lipofectamine 2000 (Invitrogen). The
following RNA interference sequences (Invitrogen) were used:
control siRNA, forward 50-GCUCCGGAGAACUACCAG
AGUAUUA-30; HIF-2a siRNA, forward 50-CAGGUGGA
GCUAACAGGACAUAGUA-30; RelA siRNA, forward
50-AUCCGGUGACGAUCGUCUGUAUCUG-30.
Proteome profiler
Cells (1.2 106) were incubated for 48 h in Dulbecco’s
modified Eagle’s medium containing 10% fetal calf serum.
Supernatants were harvested and treated according to
manufacturer’s protocol (Human Angiogenesis Array kit,
R&D Systems Europe, Abingdon, UK). Proteome profiler
arrays were carried out in triplicates and data are presented as
ratios relative to the positive controls.
Tube formation assay
Cells (1 105) were incubated for 48 h in endothelial basal
medium-2 medium containing 2% fetal calf serum and
supernatants were harvested. HUVEC cells (7.5 103) were
resuspended in 50 ml conditioned medium and plated into the
wells of Angiogenesis m-slides (Ibidi, Vitaris, Baar, Switzer-
land) coated with 3mg/ml Matrigel (BD Biosciences). Tube
formation was photographed after 6 h. Quantification was
performed either by counting the branching points, defined as
a vessel that subdivides in at least two additional vessels, or by
measuring the length of the tubes using Axio Vision software
(Carl Zeiss).
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Supplementary Figure S1 
PHD2 protein levels were determined in parental and shRNA control MCF-7 cells by 
immunoblotting. Cells were cultivated under hypoxic conditions (1% O2) for up to 72 
hours. 
 
Supplementary Figure S2 
Cell proliferation of parental MCF-7 cells was assessed by counting cells over 11 
days. Cells were treated with either 2 nM estradiol or 1 M of the ER antagonist 
fulvestrant. DMSO was used as solvent control.  
 
Supplementary Figure S3 
Transcript and protein levels of PHD2 in parental, shPHD2 C1 and B1 tumors were 
measured by RT-qPCR (upper panel) and immunoblotting (lower panel), 
respectively.  
 
Supplementary Figure S4 
PHD2 immunohistochemistry of parental and shPHD2 C1 MCF-7 cells.  
 
Supplementary Figure S5 
Protein levels of PHD2 were determined in pool of clones of lentivirally transfected 
shPHD2 and sh-control MCF-7 cells by immunoblotting. Cells were cultured under 
normoxic (20% O2) or hypoxic (1% O2) conditions for 24 hours. 
 
 
 
  
Supplementary Figure S6 
Membranes containing arrays of antibodies derived against human angiogenic 
factors were incubated with supernatants from parental, shPHD2 and PHD2-
reconstituted MCF-7 cells. Quantification of membrane data in lower panels are 
presented as pixel densities relative to the positive controls.  
 
Supplementary Figure S7 
Transcript levels of amphiregulin were measured by RT-qPCR in parental and sh 
amphiregulin MCF-7 cells. 
 
Supplementary Figure S8 
MCF-7 cells were cultured under normoxic conditions in the absence or presence of 
2 mM DMOG for up to 240 minutes. HIF-1 and PHD2 protein levels were 
determined by immunoblotting of total cell lysates (upper panel). Transcript levels of 
amphiregulin, PHD2 and CA9 were determined by RT-qPCR (lower panel).  
 
Supplementary Figure S9 
Amphiregulin and TNF mRNA levels were measured by RT-qPCR in parental MCF-
7 cells treated without or with 20 ng/ml TNF for the time periods indicated.  
 
Supplementary Figure S10 
Transcript levels of RelA, amphiregulin, IB, TNF and CA9 were analyzed in 
shPHD2 MCF-7 cells without or with (hatched columns) siRelA by RT-qPCR.  
 
 
  
Supplementary Figure S11 
Schematic summary of PHD2- and HIF-2-dependent amphiregulin regulation. 
Besides the classical oxygen-dependent and 2-oxoglutarate (2-OG)-dependent 
signaling pathways, regulating e.g. VEGF, PHD2 might have additional functions as 
controling amphiregulin transcription indirectly or directly involving HIF-2 and other 
cellular factors.  
 
Supplementary Table 1 
Clinico-pathological parameters of invasive breast cancer cases and relation to 
PHD2 expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1
Characteristic Number of cases (%) PHD2 low PHD2 high P -Value
273 (100%) 82 191
< 60 years 119 (43.6%) 32 87 0.320#
>= 60 years 154 (56.4%) 50 104
Pre-menopausal 55 (20.1%) 9 46 0.013#
Post-menopausal 218 (79.9%) 73 145
Invasive ductal 221 (81.0%) 65 157 0.563*
Invasive lobular 39 (14.3%) 12 27
NOS 18 (4.7%) 6 7
pT1 92 (33.7%) 27 65 0.866#
pT2 122 (44.7%) 39 83
pT3 15 (5.5%) 3 12
pT4 44 (16.1%) 13 31
pN0 103 (44.0%) 28 75 0.486#
pN1 106 (45.3%) 33 73
pN2 17 (7.3%) 5 12
pN3 8 (3.4%) 3 5
G1 49 (17.9%) 18 31 0.329#
G2 138 (50.5%) 40 98
G3 86 (31.5%) 24 62
ER-negative 45 (17.7%) 10 35 0.378#
ER-positive 209 (82.3%) 60 149
PR-negative 94 (34.7%) 28 66 0.979#
PR-positive 177 (65.3%) 53 124
HER2 0, 1+, 2+ 236 (90.4%) 74 162 0.111#
HER2 3+ 25 (9.6%) 4 21
#Chi-Square for trends, *Pearson Chi-Square
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Summary  
Hypoxia-inducible factor (HIF) 1 and 2 master the transcriptional response to local 
tissue hypoxia, a hallmark of solid cancers. Here, we report significantly longer 
patient survival in breast cancer with high levels of HIF-2α. Amphiregulin (AREG) 
and WISP2 expression was strongly HIF-2α dependent . The AREG promoter was 
strictly responsive to HIF-2α but independent of a classical HIF-DNA interaction 
motif, revealing a novel mechanism of gene regulation. Loss of AREG expression in 
HIF-2α depleted cells was accompanied by reduced activation of EGF-receptor 
family members and decreased hypoxic survival of tumor cells. Our results support a 
model in which breast cancer progression is dampened by a high HIF-2α/HIF-1α 
ratio, involving autocrine action of HIF-2 dependent growth factor secretion. 
 
Significance 
Tumor progression is intrinsically tied to clonal selection of tumor cells with acquired 
phenotypes allowing to cope with a hostile microenvironment. In practice, cytotoxic 
therapies may further enhance this selection pressure, often leading to relapse of 
the disease after an initial phase of tumor mass reduction. Our findings imply that 
HIF-2α mediated autocrine growth signaling in breast cancer sustains a state of 
cellular autarchy, thereby masking unfavourable growth conditions. Importantly, HIF-
2α/AREG/WISP2 expressing tumors were associated with luminal tumor 
differentiation, indicative for a better response to classical treatment. In summary, 
shifting the HIF-α balance towards an HIF-2 dominated phenotype could offer a 
novel approach in breast cancer therapy  
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Introduction 
A mismatch between metabolic demand and oxygen delivery leads to locally 
occurring hypoxia and cellular energy crisis in solid tumors. Hypoxia-inducible 
factors (HIFs) mediate the transcriptional adaptation of hypoxic cells to these 
microenvironmental conditions (Bertout et al., 2008). HIFs are composed of 
constitutively expressed β-subunits and one out of two oxygen-labile α-isoforms, 
resulting in transcriptionally active HIF-1 and HIF-2 heterodimers, respectively. 
Though structurally highly similar, specific roles of HIF-α isoforms in tumorigenesis 
have been defined (Patel and Simon, 2008; Semenza, 2010). Interestingly, ongoing 
hypoxia in a variety of human cancer cell lines leads to a specific downregulation of 
HIF-1α while HIF-2α protein levels rather increase, suggesting adaptive activation of 
the hypoxia-responsive pathway during acute and chronic tissue hypoxia 
(Holmquist-Mengelbier et al., 2006; Stiehl et al., 2006). A transient activation of HIF-
1 could also be observed in growing tumors in vivo using an allografted murine 
tumor model (Lehmann et al., 2009). As a consequence of the low structural order of 
neoplastic tissues and given the enormous plasticity of the tumor sustaining 
vasculature, spatial and temporal tumor oxygenation is highly variable (Dewhirst et 
al., 2008; Lehmann et al., 2009). Thus, we speculated that acute temporal 
fluctuations in tumor oxygenation preferentially induced HIF-1, while chronically 
hypoxic tumor areas would be marked by enhanced HIF-2 levels. To study the 
transcriptional ramifications of distinct accumulation tendencies of HIF-αs under 
acutely and chronically hypoxic conditions, we stably downregulated HIF-1α and/or 
HIF-2α by short hairpin RNA interference in a cellular model of hormone-sensitive 
breast cancer.  
HIF-α isoform specific expression profiling by quantitative PCR revealed 6 
groups of target genes with highly similar temporal transcription profiles. Target gene 
specificity was indeed marked by phaseal expression patterns, indicating HIF-1 as 
the dominant effector of acute responses to oxygen deprivation , while HIF-2 activity 
was preferentially active at sustained hypoxia and particularly in the absence of HIF-
1. These cellular mRNA data were further correlated with protein levels in 282 breast 
cancer samples and associated with patient survival times.  
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Results  
 
HIF-1α dominates the acute response to hypoxia by suppressing HIF2A gene 
expression 
As described earlier (Stiehl et al., 2006), HIF-1α protein levels in parental 
MCF-7 cells cultured for up to 72 hours at 1% oxygen where maximally induced after 
4 hours of hypoxic exposure and constantly declined during prolonged hypoxia, 
while HIF-2α levels showed delayed induction kinetics with peak levels observed 
after 24-48 hours (Figures 1A-C). Surprisingly, cell lines depleted of HIF-1α 
(shHIF1A #16, 21 and 24, respectively) had strikingly increased HIF-2α levels 
compared to the parental cell pool and HIF-2α protein was steadily rising under 
chronic hypoxia (Figure 1A). A similar increase in HIF-2α transcript levels under 
prolonged hypoxia was observed only in the absence of HIF-1α (Figure 1D, lower 
panel), indicating a model of mutual exclusion of both isoforms with a dominant role 
of HIF-1α, suppressing HIF2A/EPAS1 gene expression. In line with such a 
hierarchical model, stable knock-down of HIF-2α expression in three independent 
cell pools (shHIF2A #1, 4 and 5) had only minor effects on the remaining HIF-1α 
isoform, with slightly increased protein levels under prolonged hypoxia (Figure 1B). 
The drastic drop in HIF-1α transcript levels observed in response to acute hypoxia (8 
hours) did not affect protein levels at the same sampling time (Figures 1B and D), 
suggesting at least partially independent regulation on the mRNA and protein levels.  
Among the HIF target genes, hypoxically induced HIF prolyl-4-hydroxylases 
PHD2 and PHD3 as well as the regulator of protein translation REDD1 have been 
implicated in regulating HIF-α protein expression under hypoxic conditions 
(Brugarolas et al., 2004; Minamishima et al., 2009; Stiehl et al., 2006). While basal 
levels of PHD2 were unaffected in both HIF-α knock-down models, the hypoxic 
induction of PHD2 was abolished specifically in the absence of HIF-1α Figures 1A 
and B). Notably, knock-down efficiency for all HIF-α cell lines and pools was >80% 
and HIF-1α knock-down proved sufficient to abrogate expression of carbonic 
anhydrase 9 (CA9), another well characterized HIF target gene (Wykoff et al., 2000) 
(Figures 1A and D). Both, PHD3 and REDD1 hypoxic expression kinetics were 
markedly delayed in the absence of HIF-1α, but only PHD3 showed 2 to 3 fold 
increased hypoxic protein accumulation in shHIF2A cell pools (Figures 1A and B). 
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To test if residual hypoxic induction of PHD3 and REDD1 was caused by 
redundancy of HIF-α isoforms, a double-knock down of both isoforms was 
generated. As shown in Figure 1C, hypoxic induction of PHD3 was fully lost in 
shH1A/H2A double knock-down pools and REDD1 was only marginally induced by 
hypoxia, confirming that the delayed hypoxic response observed for both proteins in 
shHIF1A clones indeed was mediated by HIF-2. 
 
HIF-α isoforms determine target gene kinetics rather than specificity 
Prompted by the variability of the hypoxic response and target-specificity of 
HIF-α isoforms, we were interested in testing whether our model cell lines would 
prove useful to identify novel profiles of co-regulated genes in a setting of acute and 
chronic hypoxia. Temporal gene expression patterns of 34 known HIF target genes 
(Aprelikova et al., 2006; Elvidge et al., 2006) were analyzed for HIF-1 and HIF-2 
dependency by quantitative PCR in cells exposed to 1% oxygen for 4-72 hours. 
Hierarchical clustering of the samples identified a delay of hypoxic target gene 
expression in HIF-1α knock-down cells as the main feature caused by loss of this 
HIF-α isoform, while chronically hypoxic samples with HIF-1α knock-down clustered 
close to the respective samples in parental MCF-7 (Figure 2A). In contrast, all 
hypoxic timepoints from HIF-2α depleted cells clearly clustered from parental and 
shHIF1A knock-down MCF-7, indicating that HIF-2α is more than a “tardy” substitute 
for HIF-1α. 
Unbiased grouping of putatively related hypoxic gene expression profiles 
applying k-means clustering resulted in 6 distinct groups with 2-9 set members 
(Figure 2B). The mean hypoxic expression profiles from all members in one group 
showed surprisingly low variability, implying the existence of mutual regulatory 
mechanisms of hypoxic gene activation (see red curves in Figure 2C representing 
log2 ratios of relative gene expression levels). As reported previously, the large 
majority of genes (e.g. glycolytic enzymes and genes involved in metabolic 
adaptation to low oxygen availability) were predominantly depending on HIF-1α (Hu 
et al., 2003; Iyer et al., 1998; Semenza et al., 1994). Nevertheless, our kinetic 
profiling revealed subtle differences in HIF-α dependency, resulting in a novel 
grouping irrespective of known gene functions. Group 1 contains the two genes with 
highest hypoxic induction factors, and essentially required HIF-1α for gene 
transcription, highlighting their putative value as hypoxia marker genes. Group 2 
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encompassed target genes such as PHD3 with delayed hypoxic induction in the 
absence of HIF-1α and complete loss of hypoxic induction when both HIF-α 
isoforms were ablated, suggesting that these genes are required in both acute and 
chronic hypoxia. Group 6 included genes with a highly similar regulation in response 
to HIF-α isoforms, but differed from group 2 by a transient expression profile in 
parental MCF-7, categorizing these genes as markers of acute hypoxia. Genes in 
group 4 were also transiently upregulated by hypoxia in parental MCF-7, but fully 
lost hypoxic induction when HIF-1α was missing. Rather unexpectedly, group 5 
genes, including classical HIF target genes such as vascular endothelial growth 
factor (VEGF) and glucose transporter 1 (GLUT1), were only marginally affected by 
depletion of one HIF-α isoform and were robustly induced by hypoxia even when 
both HIF-α isoforms were suppressed. Of note, HIF-1α has been found to form 
kinetically stable complexes with the native VEGF promoter with a half-life of more 
than 1 hour (Yu and Kodadek, 2007). While it is unclear, how these findings relate to 
the dynamics of promoter-bound HIFs in general, one might suspect that certain 
promoter environments stabilize DNA-bound HIFs more efficiently than others and 
thus still strongly respond to hypoxia if only low levels of HIFs are present.  
Only few genes were identified which were selectively activated by HIF-2. All 
genes downregulated in the absence of HIF-2α were only modestly induced by 
hypoxia in parental cells but were strikingly super-induced at late time points in the 
absence of HIF-1α. Since this observation could reflect the robust hypoxic induction 
of HIF-2α mRNA and protein in shHIF1A cell lines, we re-analysed the data with 
specific focus on genes with highest expression levels under these conditions: 
Surprisingly, mRNA levels of IGFBP3, LOXL2 and EGFR followed a similar 
expression profile with pronounced hypoxic induction in shHIF1A cells, though 
transcript levels of these genes were only mildly affected by knock down of HIF-2α 
(Figure S1). Obviously, either HIF-α isoform can induce this set of genes, while HIF-
2α seems to be a particularly potent activator.  
 
HIF-2α/AREG/WISP2 defines a positive prognostic axis in human breast 
cancer 
To study the selective role of HIF-α isoforms in breast tumorigenesis, tissue-
microarrays (TMAs) of tumor samples derived from 282 breast cancer patients with 
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primary mamma carcinoma were stained for HIF-1α and HIF-2α. Antibodies used for 
immunohistochemical staining of paraffine-embedded tissue sections were validated 
for target specificity on a test array composed of equally fixed and embedded cell 
pellets from respective HIF-α knock-down cell lines (Figure S2). While overall 
survival of patient cohorts with low versus high nuclear expression of HIF-1α in 
neoplastic cells did not differ, patients with HIF-2α expressing tumors lived 
significantly longer (p<0.01, Log rank test) than those with tumors expressing little or 
no HIF-2α (Figure 3A)  In line with this observation, HIF-2α expression levels in 
tumors correlated with low tumor grading (p<0.01, Spearman’s rho), while in cases 
with high expression levels of HIF-1α a significant association (p<0.01, Spearman’s 
rho) with disseminated decay of lymph nodes was observed (Figure 3B).  
Given the low number of selectively HIF-2α regulated target genes found in 
MCF-7 cells, TMAs were further stained for inositol-1,4,5-triphosphate receptor type 
1 (ITPR1), plasminogen activator inhibitor-1 (PAI1), Wnt-1-inducible signaling 
pathway protein-2 (WISP2) and amphiregulin (AREG), an epidermal growth factor 
(EGF) family member which we recently identified as dramatically downregulated in 
MCF-7 cells lacking HIF-2α (Bordoli et al., 2010). Immunohistochemical analyses of 
CA9 and GLUT1 were included as established histological markers of tissue hypoxia 
(Tomes et al., 2003; Wykoff et al., 2000). Rank order correlations confirmed that 
AREG and WISP2 were significantly more abundant in tumors also positive for HIF-
2α with correlation coefficients of 0.442 (p<0.01; n=192) and 0.264 (p<0.01; n=192), 
while PAI1 and CA9 showed no specific association with one particular HIF-α 
isoform, though both PAI1 and CA9 significantly correlated with HIF-α expression in 
general. No correlation was observed between ITPR1 and HIF-α expression levels. 
Uniquely amongst the proteins tested, GLUT1 and WISP2 levels reciprocally 
correlated with HIF-α isoforms, indicating that these factors might be useful to 
discriminate the dominant HIF-α isoform in breast cancers (Figure 3B, right panel). 
Kaplan-Meier survival curves of patient subgroups whose tumors expressed 
both, AREG and WISP2 at high levels, revealed a significantly improved survival 
time (p<0.01; Log rank test) if compared to cohorts with expression of only one or 
neither of the growth factors (Figure 3C-D). To test for a putative relation between 
expression of HIF-2α, AREG and WISP2 we examined the co-aggregation of either 
parameter in patients where all three factors could be assessed (n=192). In the large 
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majority (76-84%) of cases aggregation with at least one other factor was observed 
and a substantial fraction (35-43%) was positive for all three features. Remarkably, 
exclusive expression of either HIF-2α, AREG or WISP2 alone was rare and ranged 
from 9-16% of all cases only (Figure 3E).  
 
The WISP2 and AREG promoters are predominantly activated by HIF-2α 
 Motivated by the clinical evidence for a relation between HIF-2α, AREG and 
WISP2 expression and the prospective value of all three proteins as prognostic 
beneficial factors, we set out to investigate the molecular mechanisms underlying 
co-regulation of both growth factors. While hypoxic regulation of endogenous WISP2 
transcript levels at least partially involved also HIF-1α, AREG mRNA was non-
responsive to oxygen deprivation and basal levels were strikingly downregulated in 
both shHIF2A and HIF-α double knock-down MCF-7 pools (Figure 4A). Of note, 
endogenous gene expression and HIF-α dependency was fully recapitulated when 
transfecting MCF-7 cells and respective knock-down derivatives with luciferase 
reporter gene constructs driven by the promoters of the human WISP2 and AREG 
genes, indicative for transcriptional control rather than altered transcript stability 
(Figure 4B). Re-expression of shRNA-insensitive HIF-2α in MCF-7 shHIF2A led to a 
dose-dependent induction of WISP2 and AREG promoter activities, while only minor 
or no such effects were observed when cells were transfected with equal amounts of 
a HIF-1α expression plasmid (Figure 4C). 
 
The AREG 5'-UTR is essential for transcriptional activation by HIF-2α 
 We previously mapped the minimal HIF-2α responsive region of the human 
AREG promoter (Bordoli et al., 2010). Surprisingly, this region encompassing 120 
nucleotides in both directions of the transcriptional start site (Figure 5A, upper panel) 
does not contain the consensus HIF binding site (HBS) 5’-RCGTG-3’ (Wenger et al., 
2005), although strong activation by forced expression of HIF-2α was observed 
(Figure 5A, lower panel). The luciferase reporter gene construct pGL(P2P) driven by 
the human PHD2 promoter demonstrated functional activity of exogenous HIF-1α 
expression and served as hypoxic control. Deletion of a major part of the AREG 5'-
UTR completely abolished the co-activating effect of HIF-2α overexpression while 
basal AREG promoter activity was retained, suggesting an essential role of the 5'-
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UTR in regulating AREG transcription (Figure 5A). However, the isolated AREG 5'-
UTR failed to confer HIF-2α responsiveness to the heterologous reporter gene 
construct pGL3prom, driven by the SV40 minimal promoter (Figure 5B, upper panel), 
whereas the HIF-dependent enhancer element derived from the human PHD2 
promoter in the same context readily responded to hypoxia and HIF-1α over-
expression (Figure 5B, lower panel).  
 
HIF-2α mediated activation of the AREG promoter requires cooperative sites 
Since HIF-2α regulation of the AREG promoter could not be attributed to the 
canonical HIF pathway (lack of hypoxic inducibility, absence of a functional HBS), 
phylogenetic foot-print analyses were applied to identify other conserved regulatory 
elements in the minimal HIF-2α responsive region. Genomic sequences of AREG 
orthologs derived from 15 mammalian species with a conserved TATA-box were 
subjected to multiple sequence alignments, highlighting four elements of at least 3 
base pair length with sequence similarities of >90% (Figure 5C, black boxes). 
Confirming our approach, two of these sites comprised experimentally described 
functional Wilms tumor suppressor 1 (WT-1) and cAMP response element-binding 
protein (CREB) responsive elements (WRE and CRE, respectively) in the AREG 
promoter (Lee et al., 1999). In addition, conserved E-box (5’-CAGGTG-3’) and T-box 
(5’-CACACCT-3’) elements were identified, putatively serving as recognition 
interfaces for basic Helix-Loop-Helix (bHLH) and T-box DNA-binding domains.  
Disruption of the WRE (∆WRE) as well as two truncations of the AREG 5’-
UTR (pAREG-∆SacI and pAREG-∆SmaI; Figure 5C) significantly attenuated the 
specific responsiveness to HIF-2α of the respective reporter constructs (Figure 5D). 
Although mutation of the CRE site (∆CRE) reduced basal AREG promoter activity by 
75% as expected (data not shown), induction by HIF-2α was fully preserved. 
Mutation of the putative E-box (∆E-box) and T-box (∆T-box) motifs neither affected 
the basal reporter activity nor the response to forced expression of HIF-α (Figure 
5D)   
 
Autonomous cell growth is impaired in cells lacking HIF-2α  
 To test if decreased expression of WISP2 and AREG affects mitogenic 
signaling in HIF-2α depleted cells, the phosphorylation status of 16 receptor tyrosine 
kinases (RTKs) was assessed in MCF-7 cells and HIF-α knock-down pools. As 
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shown in Figure 6A, EGF and ErbB4 receptors were hypo-phosphorylated in serum-
starved shHIF2A pools (0.1% FCS for 20 hours) when compared to the parental line. 
Concomitantly, reciprocal activation of the EGF-R was observed in shHIF1A pools, 
possibly explained by increased HIF-2α activity in these cells. Besides basal 
activation of members of the EGF receptor family (EGF-R, ErbB3, ErbB4), none of 
the other screened RTKs was activated in MCF-7, emphasizing EGF signaling as a 
major mitogenic pathway in this cellular breast cancer model. Notably, stimulation of 
starved MCF-7 cells with 10% FCS exclusively activated the IGF1-R, suggesting 
autotrophic activation of the EGF pathway in this line (Figures S3A and S3B). 
Supporting this notion, stimulation of HIF-2α knock-down pools with recombinant 
AREG particularly activated EGF and ErbB4 receptors, which were both hypo-
phosphorylated in the absence of HIF-2α (Figure 6B). No receptor activation was 
observed in serum-starved cells similarly stimulated with recombinant WISP2 (data 
not shown). 
 When compared to parental MCF-7, HIF-2α depleted cells showed strikingly 
retarded proliferation at low oxygen concentration and were highly susceptible to 
serum depletion as reflected by decreased cell numbers when cultured under 
reduced FCS concentrations. Vice versa, repression of HIF-1α increased cellular 
proliferation in the presence of high FCS concentrations only, presumably due to 
synergistic action of tumor-cell derived factors with serum components (Figure 6C). 
Interestingly, these effects were exclusively observed in cells exposed to combined 
oxygen and serum starvation, an environment frequently found in solid tumors. In 
summary, hypoxia tolerance of cells depleted for HIF-2α was greatly impaired even 
in the presence of serum-derived growth factors, possibly explained by reduced 
autonomous growth factor signaling in these cells. 
 
HIF-α isoforms are reciprocally associated with luminal and basal-like breast 
cancer  
 Based on gene expression signatures, breast carcinomas have recently been 
classified into subgroups resembling their suggested origination from basal-like 
(estrogen receptor (ESR) negative) or ESR positive, luminal mammary epithelial 
cells (Perou et al., 2000). Similar transcriptional characteristics were obtained for 
more than 50 widely-used breast cancer cell lines, subsequently categorized 
according to their gene cluster segregation as basal A, basal B or luminal cell 
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models (Kao et al., 2009; Neve et al., 2006). Since EGFR has been established as a 
marker gene of basal epithelial cells (Nielsen et al., 2004), we wondered whether the 
AREG-EGFR/ErbB4 autocrine loop is associated with one particular subtype of 
breast carcinomas. 
 Expression data for HIF-α predictive genes identified in our study (AREG, 
PAI1, CA9 and GLUT1) as well as EGF-R family members (EGFR, ErbB2, ErbB3 
and ErbB4) and respective luminal (ESR1) and basal (KRT5) marker genes were 
extracted from a dataset which previously identified 8,750 variably expressed genes 
from 50 breast cancer cell lines (Kao et al., 2009). Of note, WISP2 was not amongst 
the genes listed. As shown in Figure 7A, AREG was highly expressed specifically in 
ESR1 positive luminal cell types, co-segregating with high transcript levels of ErbB3 
and ErbB4, but with low expression of EGFR. A second cluster with high AREG 
transcript levels included cell lines with low expression of ESR1 derived from non-
tumorigenic mammary tissue (MCF-10A, 184A1 and hTERT-HME1) and EGFR 
over-expressing SUM149 and SUM102 cell lines, both showing low levels of the 
other ErbB family member. As expected, EGFR expression was specifically high in 
basal-like cell types, possibly indicating a leading role of ErbB4 in mediating 
autocrine effects of AREG in luminal cancers.  
A highly significant correlation (p<0.01, Spearman’s rho) between HIF-
2α/AREG/WISP2 and proteins indicating luminal epithelial differentiation (ESR and 
progesterone receptor (PGR), respectively) was confirmed by immunohistochemistry 
in our cohort of 346 breast cancer patients. Reciprocally, HIF-1α as well as PAI1 and 
GLUT1 were significantly associated with expression of the basal cytokeratin KRT5 
(p<0.01-0.05), suggesting a dominant role of HIF-1α in basal-like tumors (Figure 
7B). In line with a luminal signature, AREG and WISP2 were found to be highly 
expressed in luminal cells of healthy mammary tissue (Figure 7C). Retaining 
expression of these factors thus could indicate a higher degree of tumor cell 
differentiation, which is further supported by the fact that AREG and WISP2 
negatively correlated with tumor grading (with Spearman’s rho equalling -0.169; 
p<0.01 and -0.233; p<0.01, respectively). 
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Discussion 
Pioneering work using genetically modified mouse embryonic fibroblast with 
targeted disruption of both Hif1a alleles suggested a predominant role of HIF-1α for 
regulating gene expression in response to hypoxia (Park et al., 2003), a finding that 
was confirmed for a limited number of classical HIF target genes in human cell lines 
using transient RNA interference against both HIF-α isoforms (Sowter et al., 2003). 
However, expression analyses in a renal clear cell carcinoma-derived cell line 
deficient for HIF-1α revealed preserved hypoxic induction of many known HIF target 
genes, indicating that effectively both HIF-α isoforms contribute to hypoxia-induced 
transcription (Hu et al., 2003). Domain swapping experiments between HIF-1α and 
HIF-2α provided experimental evidence for interchangeability of the DNA binding 
portion of either isoform and attributed gene selectivity to the N-terminal 
transactivation domains of HIF-α (Hu et al., 2007; Lau et al., 2007). Indeed, genome-
wide promoter tiling arrays identified a common 5’-RCGTG-3’ binding motif for both 
HIF-1 and HIF-2 which is identical to our previously published  consensus core 
hypoxia response element (HRE) defined by >70 characterised HIF target genes 
(Mole et al., 2009; Wenger et al., 2005). Remarkably, almost all HIF-2  binding gene 
loci were also bound by HIF-1 with high stringency, while a substantial number of 
loci bound HIF-1 exclusively  proposing that HRE-bound HIF-2 can be fully integrated 
into the classical pathway activated by HIF-1. Yet, 15% of the HIF-2 (and even 30% 
of HIF-1) binding regions identified in the same study did not contain any consensus 
5’-RCGTG-3’ motif (Mole et al., 2009), calling for alternative modes of HIF-DNA 
interaction.  
The HIF-2α responsive AREG promoter described in this study represents an 
example of such an HRE-independent gene regulation. Target gene specificity in 
this case likely arises from additional trans-acting factors and/or cis-regulatory 
elements that cooperate specifically with HIF-2α. In a variety of HIF-2α selective 
promoters (including the WISP2 promoter) HREs have previously been reported to 
co-operate with ETS family transcription factor binding sites (Aprelikova et al., 2006; 
Elvert et al., 2003; Hu et al., 2007; Le Bras et al., 2007; Wang et al.), and HIF-2α  
has been shown to physically interact with ETS-1 and ELK-1 (Aprelikova et al., 
2006; Elvert et al., 2003). Other HIF-2α regulated genes at least contained one 
consensus HRE (Covello et al., 2006; Yamashita et al., 2008; Yang et al., 2010), 
although the stringency with which the core HRE has been determined was 
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sometimes lowered to only half-sites of the 5’-RCGTG-3’ motif (Saito et al., 2010). 
Notably, no ETS-binding 5'-GGA(A/T)-3' core motif is present in the minimal HIF-2α 
responsive AREG promoter region, suggesting the existence of a so far 
unrecognized pathway.  
By phylogenetic and subsequent mutational analysis of the minimal AREG 
promoter we identified a conserved WRE, mediating HIF-2α specific activation of 
AREG expression in MCF-7 breast cancer cells. Previous work identified the WT1(-
KTS) splice variant as a potent transcriptional activator binding to this particular site 
(Lee et al., 1999). We could not detect any expression of WT1 mRNA in MCF-7 cells 
which is in line with a previous study on expression and epigenetic regulation of 
WT1 in human breast cancers (Loeb et al., 2001). Thus, a so far undefined WRE 
binding activity is likely to mediate AREG expression in response to HIF-2α. We 
cannot conclude from our experiments whether this regulation requires direct binding 
or indirect recruitment of HIF-2α to the DNA. Alternatively, induction of another 
transcription factor by HIF-2 might be involved.  
Evidence supporting a model of a shared HIF-2α/AREG/WISP2 pathway 
arises from clinical data of 346 breast cancer patients, where a strikingly good 
correlation of either growth factor specifically with HIF-2α was observed. Only 
patients with high levels of both AREG and WISP2 showed similarly prolonged 
survival times like the HIF-2α positive cohort, indicating a concerted action of these 
proteins. Contrary to our results, another recent study found HIF-2α associated with 
distant recurrence and poor outcome in invasive breast cancer (Helczynska et al., 
2008). HIF-2α antibody quality has been validated in both studies and hence is 
unlikely to explain the discrepancy. However, Helczynska et al. analysed breast 
cancer specific survival whereas our stratified analyses considered overall survival. 
In agreement with our data showing significant correlation of HIF-1α expression with 
disseminated disease stages, conditional deletion of HIF-1α in the mammary 
epithelium of mice expressing the PyMT oncoprotein resulted in retarded tumor 
growth and decreased pulmonary metastasis (Liao et al., 2007). 
HIF-2α has been discussed as a critical mediator of renal tumorigenesis by 
enhancing c-Myc activity in vivo, particularly in renal cell carcinoma (RCC) 
exclusively expressing this isoform, and overexpression of HIF-2α increased 
xenografted tumor growth (Gordan et al., 2007; Gordan et al., 2008; Raval et al., 
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2005). However, we did not observe any changes in c-Myc dependent transcription 
in MCF-7 cells lacking HIF-1α (Figure S4) implying that HIF-2α/c-Myc interplay 
probably is tissue specific. Surprisingly, stabilized HIF-2α mutants promoted growth 
of xenografted RCC cell tumors and KrasG12D-driven lung tumorigenesis in mice (Kim 
et al., 2009; Yan et al., 2007), while Hif2a deletion in the same lung cancer model 
likewise increased tumor burden (Mazumdar et al., 2010). Though contradictory at 
first sight, Mazumdar et al. propose an appealing model where forced expression of 
HIF-2α enhances tumor growth by activation of tumor promoting target genes, while 
genetic silencing of HIF-2α leads to loss of tumor suppressor genes also boosting 
tumorigenesis (Mazumdar et al., 2010).  
What could be the mechanism behind such a dual role of transcriptional 
regulation by a single factor? Interestingly, we identified two distinct groups of HIF-2 
regulated genes: one set was particularly upregulated by HIF-2α in the absence of 
HIF-1α but still responding to hypoxia in a HIF-1α dependent fashion, whereas 
another set was exclusively restricted to HIF-2α. Therefore, HIF-2α could act 
bidirectionally via a canonical HRE-mediated pathway overlapping with HIF-1α plus 
an HRE-independent HIF-2α specific mechanism.  
Intriguingly, all genes that clustered in HIF-2α affected groups were either 
transmembrane (ITPR1, EGFR) and/or secreted proteins (IGFBP3, LOXL2, PAI1, 
WISP2, AREG), suggesting a novel role of HIF-2α in regulating intercellular 
communication. Supporting this hypothesis, EGF-R and ErbB4 receptor activation 
was significantly lower in the absence of HIF-2α, and exactly those two receptors 
were predominantly activated by AREG. While our work was in progress, another 
study reported similarly reduced EGF-R phosphorylation in human glioma, lung and 
colon carcinoma cell lines depleted of HIF-2α, postulating a widespread mechanism 
of HIF-2α mediated growth control in human cancers (Franovic et al., 2009). 
 To the best of our knowledge, AREG establishes the first direct link between 
HIF-2α dependent transcription and EGF-R family activation in human breast 
cancers. AREG co-segregated with marker genes predictive for a luminal subtype of 
breast cancer, characterized by low EGF-R expression levels (Perou et al., 2000). 
Thus, ErbB4 might be the prime target of HIF-2α/AREG dependent activation, as 
transcript levels of this EGF receptor family member were particularly high in cell 
lines simultaneously expressing AREG. Moreover, we found a strong correlation of 
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HIF-2α, AREG and WISP2 protein levels in tumor samples with luminal 
differentiation, providing evidence that the HIF-2α specific transcriptional pathway 
could play an important role in maintaining a non-invasive phenotype, as it has been 
reported for tumors expressing WISP2 before (Banerjee et al., 2008; Fritah et al., 
2008). 
Growth of MCF-7 cells depleted of HIF-2α was impaired under oxygen and nutrient 
limiting conditions in vitro, but a negative correlation of HIF-2α with tumor size and 
grade was observed in clinical samples. Such disparate proliferation characteristics 
of cells cultured in vitro or grown as xenografts in vivo have been described 
previously for A549 lung carcinoma cells with reduced levels of HIF-2α (Franovic et 
al., 2009; Mazumdar et al., 2010). Cancer cells interact with the surrounding 
microenvironment by secretion of a variety of growth factors, partially mediated by a 
HIF-2α specific transcriptional pathway. In normoxia, a balanced activation of 
canonical and HIF-2 specific pathways tightly controls energy homeostasis and 
cellular proliferation (Figure 8A). Tumor cells, however, encounter periods of severe 
oxygen starvation, ultimately selecting for phenotypes resistant to a hostile 
environment (Gatenby et al., 2007). Thus, cancer cells expressing high levels of 
HIF-2α (like those cells with suppressed HIF-1α in our study) benefit from increased 
autocrine and paracrine growth factor signaling, supporting cellular autonomy by 
masking unfavourable growth conditions. As a consequence, selection pressure in 
these cancers might be reduced and tumor progression is slowed down (Figure 8B). 
On the other hand, cells predominantly expressing HIF-1α recruit oxygen-
independent energy pathways but may suffer from decreased mitogenic signaling 
due to loss of HIF-2α specific growth factors. Increased selection pressure forcefully 
promotes tumorigenesis, eventually leading to the acquisition of invasive properties 
and dissemination of the disease (Figure 8C). Based on the recently developed 
concepts of “Adaptive Therapy”, where a stable tumor burden of higher differentiated 
tumor cells is sustained to suppress growth of slow proliferating but therapy resistant 
phenotypes (Gatenby et al., 2009), novel therapies maintaining a HIF-2α dominated 
phenotype could prove of value to treat breast cancer. 
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Experimental Procedures 
 
Cell culture and derivatives 
Human breast cancer MCF-7 cells were cultured in DMEM (high glucose, Sigma) 
supplemented with 10% FCS, 50 IU/ml penicillin and 50 µg/ml streptomycin 
(Invitrogen). Cell lines with stable HIF-1α suppression (shHIF1A #16, #21 and #24) 
were generated by transfection with a pLKO.1-puro vector expressing U6 promoter 
driven shRNA targeting nucleotides 1168-1188 of human HIF1A (NM_001530.x-
1048s1c1, Sigma). Cell clones were derived by puromycin selection (2 µg/ml) and 
ring cloning. Hypoxia kinetics were carried out at 1% oxygen and 5% CO2 in a gas-
controlled glove box (InvivO2 400, Ruskinn Technologies). 
 
shRNA constructs and lentiviral infections 
Lentiviral expression vectors encoding three shRNA sequences targeting human 
HIF2A at nucleotides 878-898 (#1, NM_001430.x-517s1c1), 927-947 (#5, 
NM_001430.x-566s1c1) and 2055-2075 (#4, NM_001430.x-1694s1c1) in a pLKO.1-
puro plasmid were purchased from Sigma. Variants of shRNA expression plasmids 
bearing a hygromycin resistance marker were generated by replacing the original 
puromycin resistance cassette in pLKO.1. Viral particles were produced in HEK293T 
cells by co-transfection of the respective transfer vector (3 µg) with the packaging 
plasmids pLP1 (4.2 µg), pLP2 (2 µg) and pVSV-G (2.8 µg, all from Invitrogen) using 
PEI transfection as described before (Stiehl et al., 2006). MCF-7 cells were infected 
with lentiviral-pseudotyped particles and cell pools were derived by puromycin (2 
µg/ml) and/or hygromycin (400 µg/ml) selection.  
 
Tissue specimen and TMA analysis 
Histopathological and immunohistochemical analyses of tumor tissues from 282 
invasive breast cancer cases diagnosed at the Institute of Surgical Pathology 
(University Hospital, Zürich, Switzerland) were performed essentially as described 
{Bordoli, 2010 #1272}. Patient age at time of diagnosis ranged from 26 to 93 years 
with a median of 61 years (mean 62). The median observation time for overall 
survival was 61 months for patients still alive at the time of analysis. In total, 74 
patients (26.2%) died during follow-up. Detailed information on the 
clinicopathological characteristics of the patients/tumors are described in Table S1. 
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Antibodies used for immunohistochemistry are listed in the Supplemental 
Experimental Procedures. 
 
Human phospho-RTK array 
The phosphorylation status of 16 receptor tyrosine kinases (RTK) has been 
assessed in parallel using Proteome Profiler 96 (R&D Systems). Briefly, 1×106 MCF-
7 cells or derivatives were grown at 0.1% FCS for 20 hours and stimulated with 
recombinant AREG (100 ng/ml; R&D Systems), WISP2 (100 ng/ml; Creative 
Biomart) or 10% FCS for up to 20 minutes. Cells were lysed immediately and protein 
concentration was determined by the Bradford method. Cellular protein (1 to 25 µg) 
was subjected to the provided two-site sandwich ELISA plate and the assay 
performed following the manufacturer’s instructions. Signals were detected using a 
luminescent image analyser (LAS-4000, FUJIFILM) and spot intensities were 
quantified with the Quantity One software package (Biorad). 
 
Supplemental Information 
Supplemental Information including Supplemental Experimental Procedures, four 
figures and one table can be found online with this article. 
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Figures 
 
Figure 1. Reciprocal induction kinetics of HIF-α isoforms: early HIF-1α, late 
HIF-2α 
(A) MCF-7 (parental) and respective shHIF1A clones (#16, 21 and 24) or three 
independent stable cell pools, lentivirally infected with different targeting sequences 
for HIF2A (B), were subjected to 1% oxygen for up to 72 hours and whole cell 
protein extracts were immunoblotted for the proteins indicated. (C) Combined knock-
down of both HIF-α isoforms was achieved by infecting clone shHIF1A #24 with 
pLKO.1-hygro shHIF2A #4. Extracts were analysed as above. (D) Transcript levels 
of parental, shHIF1A, shHIF2A and shH1A/H2A cultures were quantified by RT-
(q)PCR. Control cells (“C”) were cultured at 20% oxygen, while hypoxic ("hyp") 
probes were sampled at the same time points as shown in immunoblots. All data are 
given as mean ± SEM of three independent experiments and normalized to 
ribosomal protein L28 mRNA levels. Highest hypoxic mRNA levels in the parental 
cell line was arbitrarily defined 1 in each independent experiment. 
 
Figure 2. HIF target genes cluster with distinct hypoxic expression profiles  
(A) Dendrogram depicting hierarchical clustering of the hypoxic response in parental 
MCF-7 and HIF-α single and double knock-down cells based on expression kinetics 
of 34 known HIF target genes. (B) Transcript levels determined by RT-(q) PCR for 
known HIF target genes in parental, shHIF1, shHIF2 and double knock-down  
shH1A/H2A MCF-7 cells exposed to 1% oxygen for up to 72 hours. A heat map 
illustrates time-resolved hypoxic expression kinetics for each gene with a dynamical 
range from -3 (lowest expression) to +3 (highest expression) in blue and red, 
respectively. Data represent log2 (ratios) of the mean of three independent 
experiments normalized to L28 mRNA levels. Genes were grouped by time-resolved 
gene expression applying K-means clustering. (C) Hypoxic gene expression profiles 
of each group given as mean induction (log2 ratios) of all group members (red line 
and right y-axes). Grey-shaded areas indicate the dynamic range of the hypoxic 
response in parental cells. A representative gene of each group is also shown (bar 
graphs relate to left y-axes, mean ± SEM). 
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Figure 3. HIF-2α is a positive prognostic factor in breast cancer 
(A) Immunohistochemical detection of HIF-α isoforms in tissue micro arrays (TMAs) 
of 282 invasive breast cancer cases. Kaplan-Meier survival curves are shown for 
patients with low or high expression of either isoform. Log-rank tests (Mantel-Cox) 
were performed to compare the survival distributions of the two groups. Lower 
panels are representative immunostains of tumor tissue with low and high HIF-α 
expression. Arrowheads indicate exemplary cells with nuclear HIF-α staining. (B) 
Rank-order correlations (Spearman's rho) for HIF-α forms with clinico-pathological 
characteristics (table) and isoform pre-selective HIF target genes (right panel). 
Disease stage was assessed according to International Union Against Cancer 
(UICC, 2002). Tumors were graded according to the modified Bloom and 
Richardson system. Asterisks indicate statistical significance with *p<0.05 and 
**p<0.01. (C) Overall survival of patients with expression of either AREG or WISP2 
in primary tumors ("one"), both factors together ("both") or absence of either factor 
("none"). Statistical analyses were performed as described above. (D) 
Immunostainings of tumor tissues from six patients with low and high AREG or 
WISP2 expression, respectively. (E) Set diagram reflecting the relation between 
expression of HIF-2α, AREG and WISP2 in primary breast cancer. Only tumor 
samples where all three parameters could be accessed were included in the 
analyses (192 cases). Areas of sets are representative for the number of cases with 
respective attributes. Relative values indicate the set size in relation to the number 
of cases showing expression of at least one factor (128 cases).  
 
Figure 4. HIF-2α dependent regulation ofWISP2 and AREG promoters 
(A) Hypoxic expression profiles of WISP2 and AREG in the presence and absence 
of HIF-α isoforms in MCF-7 cells. Transcript levels of normoxic cultures ("C") were 
compared to those cultured at 1% oxygen ("hyp") for 4, 8, 24, 48 and 72 hours. Data 
are given as mean ± SEM of 3 independent experiments. (B) HIF-2α affects WISP2 
and AREG promoter activities. MCF-7 parental cells, no target control shRNA 
("pLKO.1-puro") and HIF-α knock-down pools were transfected with reporter 
constructs driven by the human WISP2 or AREG promoters. Data (mean ± SEM, 
n=3) was normalized to normoxic expression levels of the human PHD2 promoter 
and differences in transfection efficiency were controlled by co-expression of renilla 
luciferase. (C) Overexpression of HIF-2α strongly activates the human WISP2 and 
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AREG promoters. MCF-7 shHIF2A pools were co-transfected with either human 
WISP2 (left panel) or AREG (right panel) reporter constructs and increasing 
amounts of HIF-α encoding expression plasmids (200, 400 and 800 ng DNA, 
respectively). The empty expression vector ("empty") served as negative control. 
Transfected cells were cultured for 24 hours at 20% or 1% oxygen and luciferase 
activity was determined.  
 
Figure 5. Phylogenetic footprint analysis of the minimal HIF-2α responsive 
AREG promoter 
(A) Scheme depicting the minimal HIF-2α responsive AREG reporter construct and a 
deletion mutant lacking the AREG 5'-UTR. Numbers are relative to the 
transcriptional start site (TSS). Reporter constructs (200 ng) were co-transfected 
with 800 ng of HIF-α expression plasmids or empty vector. The human PHD2 
promoter pGL(P2P) and the promoterless pGL2b served as controls. Luciferase 
activity was determined of cells cultured at 20% or 1% oxygen for 24 hours. (B) The 
isolated AREG 5'-UTR is not sufficient to mediate activation by HIF-2α. SV40 
minimal promoter driven luciferase fused to the AREG 5'-UTR was co-transfected 
with HIF-α expression plasmids or empty vector and luciferase activity was 
measured as described above. The UTR-lacking plasmid (pGL3prom) and the 
hypoxia-responsive reporter pSVL(P2P)95bp served as controls. (C) Sequence 
similarity of the AREG promoter in 15 different species harbouring a 100% 
conserved TATAAA box (lower panel). Conserved elements of at least 3 bp with 
>90% sequence similarity were mutated as indicated in the upper scheme of the 
reporter construct. (D) Mutated and 3'-truncated (Sac I and Sma I, respectively) 
AREG reporter constructs were co-transfected with HIF-α expression plasmids and 
empty vector as before. Data is shown as responsiveness to HIF-α isoforms 
normalized to the empty expression vector derived from three independent 
transfections analysed in triplicates. Asterisks indicate significant differences 
between HIF-1α and HIF-2α responsiveness of the respective constructs (Tukey's 
Multiple Comparison Test).  
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Figure 6. Basal EGF and ErbB4 receptor activation is attenuated in cells 
lacking HIF-2α  
(A) Human Phospho-RTK Array of MCF-7 parental and HIF-α knock-down pools. 
Representative images of cultures grown at 0.1% FCS for 20 hours are shown. 
Phosphorylation levels of the EGF receptor family were quantified from at least three 
independent cultures. Asterisks indicate significant differences of the mean as 
determined by unpaired Stundent’s t-tests (*p<0.05; ***p<0.001). (B) Recombinant 
AREG activates EGF and ErbB4 receptors in shHIF2A knock-down cells. MCF-7 
shHIF2A cells were grown at 0.1% FCS for 20 hours and stimulated with 
recombinant AREG (100 ng/ml) for up to 20 minutes. Phosphorylation levels of EGF 
receptor family members were quantified from three independent experiments. 
Strongest phosphorylation levels in each experiment were set as 1.0 and data are 
given as mean ± SEM. (C) Combined oxygen and growth factor starvation in MCF-7 
parental and respective HIF-α knock-down pools. Cells were cultured for 72 hours at 
1% oxygen in the presence of 0.1-10% FCS. Control cultures were grown at 20% 
oxygen in media supplemented with 10% FCS. Cell proliferation was determined by 
MTT assay and data expressed as relative growth [in %] compared to cells cultured 
at control conditions (mean ± SEM) 
 
Figure 7. HIF-2α/AREG/WISP2 are co-expressed in luminal breast cancers 
(A) Expression data for HIF-α predictive genes (AREG, PAI1, CA9 and GLUT1) and 
EGF- receptor family members (EGFR, ErbB2, ErbB3 and ErbB4) and respective 
luminal (ESR1) and basal (KRT5) marker genes in 50 breast cancer cell lines were 
extracted from (Kao et al., 2009). Hierarchical clustering (Euclidean distance) of 
expression values are depicted with a dynamical range from -3 (lowest expression) 
to +3 (highest expression) in blue and red, respectively. Cells have been 
characterized 
previously as basal A (red), basal B (green) or luminal (blue) cell models according 
to cluster segregation with respective gene signatures (Kao et al., 2009; Neve et al., 
2006). Black squares indicate missing data points. (B) Rank-order correlations 
(Spearman's rho) for protein expression of HIF-α isoforms and pre-selective HIF 
target genes with markers of luminal (ESR and PGR, left panel) as well as basal 
(KRT5 and EGF-R, right panel) cancer subtypes. Data were derived from 
immunohistochemistry of 346 tumor specimen for each protein. Asterisks indicate 
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statistical significance with *p<0.05 and **p<0.01. (C) AREG and WISP2 are highly 
expressed in luminal cells in healthy breast tissue. Representative 
immunohistochemistry stains for AREG and WISP2 of a normal mammary lobule 
(left images). Arrowheads indicate luminal secretory and basal myoepithelial cell 
layers of healthy mammary epithelium (right images). 
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Figure 8. Autocrine growth signaling in breast tumorigenesis involves non-
canonical functions of HIF-2α 
(A) At physiological oxygenation as found in developed tissues, the canonical (HRE-
mediated) HIF pathway and HIF-2α specific signaling cooperatively regulate cellular 
energy metabolism and proliferation, respectively. HIF-α protein levels (left panel in 
all subfigures) reflect quantified band intensities (mean ± SEM) of immunoblots as 
presented in Figure 1. Highest protein levels observed in parental MCF-7 for either 
isoform were arbitrarily defined as 1. (B) Tumor cells overexpressing HIF-2α 
(simulated by knock-down of HIF-1α in our study) show increased activity of the 
autotrophic AREG/EGFR/ErbB4 pathway. In vivo, HIF-2α mediated cellular 
autonomy might slow down tumor evolution, e.g. by masking a hostile 
microenvironment. (C) Tumor cells with low expression of HIF-2α lack autotrophic 
growth signaling, increasing their addiction to microenvironmental growth stimuli. 
Starvation and a glycolytic phenotype boost tumor progression in vivo. 
 
???
??????
??????
? ? ?? ?? ??
??
??
???
?
?
?
??
????
? ? ?? ?? ??
??
??
???
? ? ?? ?? ??
??
??
???
? ? ?? ?? ??
??
??
???
???????? ??????????? ??????????????????????
??????
????
???
???????
?
???????? ?????????? ????????????????????
?
? ? ?? ?? ??
??
??
???
? ? ?? ?? ??
??
??
???
? ? ?? ?? ??
??
??
???
? ? ?? ?? ??
??
??
???
?????
? ???????? ?????????
? ? ?? ?? ??
??
??
???
? ? ?? ?? ??
??
??
???
???
??????
??????
?
?
?
??
????
??????
????
???
???????
?????
???
??????
??????
????
??????
????
???
???????
?????
???
?
??
?
?
??
?
?
?
??
?
??
??
?
?
?
??
?
???
???
???
???
???
???
???
?
??
?
?
??
?
?
?
??
?
??
??
?
?
?
??
?
?
?
?
??
?
??????????????????????
? ???
????????
? ???
???????
? ???
???????
? ???
?????????
? ???
????????
? ???
???????
? ???
???????
? ???
?????????
???????
????
??????
??????
?????
???
???
????
??????
??????
?????
?????
??????
??????
??????
??????
????
?????
????
?????
?????
????
????
?????
?????
?????
??????
??????
?????
??????
?????
?????
?????
????
? ? ?? ??????
???????? ??????? ???????
?? ?
? ? ?? ??????
?? ?
? ? ?? ??????
?? ?
? ? ?? ??????
?? ?
???????
??? ??
?
??
?
?
??
?
??
?
?
??
?
??
?
?
??
?
??
?
?
??
?
??
?
?
??
?
??
?
?
??
???
??
??
??
??
?
?
???
???
???
??
??
??
?
???
???
???
???
???
???
???
???
???
???
???
???
???
???
???
???
???
???
??
??
?
?
??
??
??
?
?
???
???
???
???
???
???
???
???
???
??
??
??
??
??
??
??
?
?
?
?
???????? ??????? ??????? ?????????
???? ???? ???? ????
?
?
?
??
?
?
?
??
?
??
??
?
?
?
??
?
?
?
?
?
??
?
?
?
??
?
??
??
?
?
?
??
?
??
?
?
?
??
?
?
?
??
?
??
??
?
?
?
??
?
?
??
?
?
??
??
?
???
????
?
?
??
?
?
??
?
???
?
?
??
?
?
?
?
??
?
??
?
?
?
??
?
??
??
?
?
?
??
?
?
?
?
?
?
??
?
?
?
??
?
??
??
?
?
?
??
?
?
?
?
?
?
?
?
??
?
?
?
??
?
??
??
?
?
?
??
?
?
??
?
?
??
??
?
???
????
?
?
??
?
?
??
?
???
?
?
??
?
?
?
??
?
?
??
??
?
???
????
?
?
??
?
?
??
?
???
?
?
??
?
?
?
??
?
?
??
??
?
???
????
?
?
??
?
?
??
?
???
?
?
??
?
?
?
??
?
?
??
??
?
???
????
?
?
??
?
?
??
?
???
?
?
??
?
?
?
??
?
?
??
??
?
???
????
?
?
??
?
?
??
?
???
?
?
??
?
?
?
????????????
???????????
???????????
????????????
????????????
????????????
??????????
?????????
?????????
??????????
??????????
??????????
?????????
?????????
??????????
??????????
??????????
??????????
?????????????
????????????
????????????
?????????????
?????????????
?????????????
?
?
???????
???????
?????????
??????????????????????
???????? ??????? ??????? ?????????
???? ???? ???? ????
???????? ??????? ??????? ?????????
???? ???? ???? ????
???????? ??????? ??????? ?????????
???? ???? ???? ????
???????? ??????? ??????? ?????????
???? ???? ???? ????
???????? ??????? ??????? ?????????
???? ???? ???? ????
???????
???????
?????????
???????
???????
?????????
???????
???????
?????????
???????
???????
?????????
???????
???????
?????????
?? ??????????
?
?
?
??
??
??
?
??
??
?
?
?
?
?
?
??
??
??
?
?
??????????????????????????????
???
???
???
? ?? ?? ?? ?? ??? ???
??????
??????????
??????????
?? ??????????
?
?
?
??
??
??
?
??
??
?
?
???
???
???
???
? ?? ?? ?? ?? ??? ???
?????????
??????????
??????
??????????????????????????
?
?
??
??
??
??
?
?
?
??
??
??
??
???????? ???????
?
??????
???
??????
??????
?
?? ??????????
?
?
?
??
??
??
?
??
??
?
?
???
???
???
???
? ?? ?? ?? ?? ??? ???
?????
????????
??????????????????????????
????
??????
????
???
????
????????
??????
????????
????????
????????
????????
????????
????????
??
?????
???????
?
?
??
??
?
?
?
????
???
????? ???? ???? ????? ??? ?????
?????
????
????
????
??????
??????
?
?
?
?
??
?
?
??
??
?
?
??
??
?? ???? ??
? ?
?
??????
?? ??????????????
?
????? ??????
??? ???
?? ??????????????
?
????? ?????
??? ???
? ??????????????
?
????? ??????
??? ???
??????
??
??
?
?
??????? ??????? ???????
??????? ??????? ???????
??????? ??????? ???????
??????? ??????? ???????
??????????????????????
??????????????
????????
?
??
?
?
??
?
?
?
??
?
??
??
?
?
?
??
?
?
?
?
?
??
?
?
?
??
?
??
??
?
?
?
??
?
?
????
????
????
????
????
???????? ??????? ??????? ????????? ???????? ??????? ??????? ?????????
???? ???? ???? ???? ???? ???? ???? ????
?????
?????
??????
??????
??????
?????
??????????????????????????
?????????????????????????????????
????? ????? ????? ????? ????? ????? ????? ?????
?????
?????
??????
??????
?????????????????????????????????
??????????????????????????
?
????
????
????
????
????
???? ???? ???? ???? ???? ???? ???? ????
??? ??? ??? ??? ??? ???? ???? ???? ???? ???? ???? ????
????????
???????
???????
???????????
????????????????????????????????????????? ????????????????????????????????????????
????????
???????
???????
???????????
?
??????
?????
??????
?????
??????
?????
??????????????????????
????
???? ????
??
??
???
???????
???????
??????
??????
???????
???????
??????
??????
????? ?????
?
??
??
?
??
??
?
??
?
??? ??? ??? ??? ??? ???
???????? ??????
??????
???? ????
????
????
????
???????????
???????????
??????????
??????????
????????????
????????????
??????
????????????????????????????????????????
?
?
????
????
????
????
??
??
??
??
????
????
????
??????????
???????
???????
????? ?????
????????
???????????
???????????
??????????
??????????
????????????
????????????
??????
???? ???
????
???
???? ???
????
?
???? ???? ???? ???? ???? ????
??????
??????
?????
??????
??????
?????
??????
??????
?????
?
?
??
?
?
?
?
??
?
?
?
??
?
?
?
?
?
??
?
?
?
??
?
?
?
?
?
?
?
?
?
??????
?????
??? ??? ??? ??? ??? ??? ???
??????
??????
?????
?
?
?
?
?
??
?
?
?
??
?
?
?
???
??????????????????????????
??????????????????????????
??????
??????
?????
??????
??????
?????
?
?
?
?
??
??
?
?
?
??
?
?
?
??
??
?
?
?
?
??
?
??
?
???? ???? ???? ???? ????
??????????????????????????
? ? ?
??????
??????
?????
?
?
?
?
??
?
?
?
??
?
?
?
?
? ? ? ? ? ??
??????????????????????????
?
???????????
????
?????????????
??????
???
????
???????????
?????????????
???
??????
?????
??????????????????????
?
?? ???
????? ?????
?????
????????????? ???
? ?? ??
????
????
????
?????
?????
?????
????
??
?
?
?
??
??
?
?
?
?
?
?
?
??
??
??
?
??
??
?
??
?
?
??
?
?
?
??
??
?
?
?
?
?
?
?
??
??
??
?
??
??
?
??
?
?
??
?
?
?
??
??
?
?
?
?
?
?
?
??
??
??
?
??
??
?
??
?
?
????? ?????
?????
???????? ??????? ??????? ?
????? ????? ?????
????
????
????
????
????
????
????
????
????????
???????
??
?
?
?
??
??
?
?
?
?
?
?
?
??
??
??
?
?
??
?
??
??
?
??
?
??
?
??
??
?
?
?
??
?
???
???
?
?
?
? ?? ??????
? ?? ??????
??? ? ??
??
??
??
??
??
???
???????
????????
???????
???????
??? ?
????????????????????????????? ????????
??
??
??
?
??
??
??
??
??
??
??
?
?
??
??
?
?
??
?
?? ???
??? ??? ??? ???
????
????
????
????
????
????
????
????
????
????
????
????
??????????????????????
????????
???????
???????
???? ?????????? ??????????????? ???? ????
?????
?????
????
????
????
???
???
??????
?
?
?
?
??
?
?
??
??
?
?
???? ?????????? ??????????????? ??? ?????????
?????
?????
????
????
????
?
?
?
?
??
?
?
??
??
?
?
? ????
????
?? ??
??
?? ??
??
?
????
??
??
??
???????
?????
???????
?????
?
?
??
??
?
?
?
?
?
??
??
??
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
??
?
?
?
?
?
?
??
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
??
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
??
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
??
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?????
???
???
????
?????
????
????
????
?????
?????
??????????????????????
????????
?
???
???
???
???
???
???
???
???
???
? ? ?? ?? ??
?
??
??
??
??
??
??
??
?
?
?
??
???????????
???????????
??????????????
?
??
?
?
?????? ??????
????????????????????? ??????????????????????
?
??
??
?
??
?? ???? ??????
?
??????
? ? ? ?? ?? ??
? ? ? ?? ?? ??
???
???????
???
???
???
???
???
???
???
???
???
???????????
??????????????
?
??
??
??????
??????
????????????????????? ??????????????????????
?
??
??
?
??
?? ???? ??????
?
??????
???????
???
???
???
???
???
???
???
???
???
???????????
??????????????
?
??
?
?
?????? ??????
????????????????????? ??????????????????????
?
??
??
?
??
?? ????
?
??????
??????
?
?
?
?????????
?????????????????????????????
?????????
?????????????????????????????
????????
?????????????????????????????
????
?????
???????
??????????????????
??????????????????????????
????????????????????
??????????????
?????????????????????
?????????????????????
?????????????????
?
??
??
??
??
??
??
??
?
?
?
??
?
??
??
??
??
??
??
??
?
?
?
??
?
?
?
?????? ??????
??????????????????????
???????????
???????????
MANUSCRIPT 
-61- 
Supplemental Information 
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Supplemental Data 
 
Supplementary Figure 1 relates to Figure 2. Hypoxia-responsive genes strikingly 
upregulated in HIF-1α knock-down cells under chronic hypoxia 
 
Supplementary Figure 2 relates to Figure 3. Validation of antibodies used for 
immunohistochemistry (IHC) on tissue microarrays (TMAs) 
 
Supplementary Figure 3 relates to Figure 6. Autotrophic activation of EGF 
receptor family in MCF-7 breast carcinoma cells 
 
Supplementary Figure 4 relates to Discussion. HIF-α knock-down only marginally 
affects c-Myc dependent gene expression in MCF-7 cells 
 
Supplementary Table 1 relates to Figure 3. Clinicopathological parameters of 
invasive breast cancer cases and relation to HIF-α isoform expression. 
 
 
Supplemental Experimental Procedures 
 
 mRNA quantification and primers 
 Plasmids and reporter gene assays 
 Immunoblotting 
 Cell proliferation/viability assays 
 Histopathologic grade and Immunohistochemistry 
 Bioinformatic analyses and statistical methods 
 
Supplemental References 
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Supplemental Data 
 
 
 
 
 
Figure S1. Hypoxia-responsive genes strikingly upregulated in HIF-1α knock-
down cells under chronic hypoxia  
Transcript expression profiles of IGFBP3, PAI1, LOXL2 and EGFR were determined 
in parental MCF-7 cells as well as in respective HIF-α knock-down derivatives. "C" 
indicates samples from cells cultured at ambient oxygen concentration while hypoxic 
("hyp") probes were sampled from cultures exposed to 1% oxygen for 4, 8, 24, 48 
and 72 hours, respectively. Basal expression levels as well as maximal hypoxic 
induction in parental cells are indicated with blue and red lines, respectively. Data are 
given as mean +SEM of three independent experiments and normalized to L28 
mRNA levels. Highest expression levels in parental MCF-7 cells were arbitrarily 
defined 1 in each independet experiment. 
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Figure S2. Validation of antibodies used for immunohistochemistry (IHC) on 
tissue microarrays (TMAs) 
(A to E) Renal clear cell carcinoma 786-0 and breast cancer MCF-7 parental cells as 
well as respective cell pools with stable expression of shHIF1A and shHIF2A (1×108 
cells) were cultured with or without 1mM DMOG for 24 hours and DMOG was 
readded 4 hours before harvest. Cell pellets were mixed with human plasma, 
coagulated by addition of thrombin and immediatly fixed by addition of 4% PFA 
solved in PBS. Coagulated pellets were embedded in paraffin and a cell pellet 
microarray was constructed as described before. Slides were subjected to an 
automated immunohistochemistry staining protocol using primary anti-HIF-1α, anti-
HIF-2α, anti-GLUT1 and anti-CA9 with respective secondary antibodies. A strong 
nuclear signal for HIF-1α was observed only in DMOG treated MCF-7 parental and 
shHIF2A cell derivatives (see arrowheads) while shHIF1A pools were widely negative 
for HIF-1α, indicating specificity of this stain (A). HIF-2α staining showend a speckled 
nuclear pattern, which was most evident in DMOG treated shHIF1A pools (see 
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arrowhead). Note, that immunoblotting confirmed higher levels of HIF-2α in the 
absence of HIF-1α (see Figure 1). In nuclei of shHIF2A pools the speckled pattern 
was largely absent (B). Specificity of the HIF-2α signal was further confirmed by 
knock-down of HIF-2α in 786-0 cells which exclusively expresses HIF-2α. Due to 
deficiency of the von Hippel-Lindau protein (pVHL) in 786-0 cells, HIF-2α escapes 
the degradation machinery at oxic culturing conditions, resulting in nuclear and 
cytoplasmatic accumulation of HIF-2α 
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Figure S3. Autotrophic activation of EGF receptor family in MCF-7 breast 
carcinoma cells 
(A) Human Phospho-RTK Proteome Profiler (R&D Systems) spot layout. Refer to the 
table for abbreviations and alternative gene product names ("ref. spot": reference 
spot). (B) IGF1-R is specifically activated in serum stimulated MCF-7 cells. Serum 
starved MCF-7 cultures (0.1% FCS for 20 hours) were stimulated with medium 
containing 10% FCS for 20 minutes and lysed according to the manufacturer's 
protocol. Receptor phosphorylation status of 16 RTKs was assessed by loading 1 to 
25 g of total protein per assay. A representative image of starved and stimulated 
MCF-7 cells is show (25 µg total protein). Phosphorylation levels of EGF receptor 
family and IGF1-R were quantified by measuring the spot intensities (Quantity 
One/Biorad). 
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Figure S4. HIF-α knock-down only marginally affects c-Myc dependent gene 
expression in MCF-7 cells 
Hypoxic transcript expression profiles of genes repressed by c-Myc activity (p21 and 
p27) as well as E2F1, which is activated by c-Myc, were determined in parental MCF-
7 cells as well as in respective HIF-a knock-down derivatives. "C" indicates samples 
from cells cultured at ambient oxygen concentration while hypoxic ("hyp") probes 
were sampled from cultures exposed to 1% oxygen for 4, 8, 24, 48 and 72 hours, 
respectively. Data is given as mean +SEM of three independent experiments and 
normalized to L28 mRNA expression. Highest expression levels in parental MCF-7 
cells were arbitrarily defined 1 in each independent experiment. 
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Table S1. Clinicopathological parameters of invasive breast cancer cases and 
relation to HIF-α isoform expression. 
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Supplemental Experimental Procedures 
 
mRNA quantification 
cDNA was generated by reverse transcription (RT) of 1-3 µg of total RNA using 
AffinityScript reverse transcriptase (Agilent). Transcript levels were quantified by 
quantitative (q) PCR using a SybrGreen qPCR reagent kit (Sigma) in combination 
with a MX3000P light cycler (Agilent). Initial template concentrations of each sample 
were calculated by comparison with serial dilutions of a calibrated standard. All data 
are expressed as ratios relative to ribosomal L28 mRNA levels. Melting point 
analyses of amplified PCR products were performed for each primer pair to verify 
specific amplification. Sequences of primers and length of specific amplicons (in base 
pairs) are given below.  
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Plasmids and reporter gene assays 
The human AREG promoter plasmids pAREG(-641/+120), pAREG(-120/+16) and the 
human WISP2 promoter have been described elsewhere (Fritah et al., 2006; Lee et 
al., 1999). A 5’-UTR regulatory element encompassing nucleotides +10 to +120 of 
human AREG was amplified by PCR and cloned into pGL3prom (Promega). 
Mutations of conserved WRE, CRE, E-Box and T-Box motifs have been generated by 
site-directed mutagenesis and are based on the minimal HIF-2α responsive AREG 
promoter construct pAREG(-120/+120) we recently described (Bordoli et al., 2010). 
Deletions of the 5’-UTR of pAREG(-120/+120) have been constructed by digestions 
with SmaI or SacI restriction enzymes and were designated accordingly. The PHD2 
luciferase reporter plasmid pGL(P2P)607wt is a truncated version of the previously 
published human PHD2 promoter (Metzen et al., 2005), while a 95 base pair element 
surrounding the HBS of the PHD2 promoter was cloned into pGL3prom to obtain 
pSVL(P2P)95bp. Forced expression of HIF-2α in stable shHIF2A #4 knock-down 
cells was achieved using a hairpin-insensitive HIF-2α expression construct with silent 
mutations in the target region as indicated in the following primer (base exchanges 
underlined): 5’-GACCAATGC AGTACCCAAACTGACTTCAATGAGCTGGAC-3’. If 
not otherwise indicated, 1×106 MCF-7 cells or derivatives were transiently transfected 
with 200 ng reporter plasmid and 800 ng of either HIF-α or empty expression vectors 
in a six-well format by PEI transfection (Stiehl et al., 2006). To control for differences 
in transfection efficiency and extract preparation, 5 ng pRL-CMV Renilla luciferase 
reporter vector (Promega) were co-transfected. Cultures were evenly split onto 12-
well plates 24 hours post transfection and exposed to 20% or 1% oxygen for an 
additional 24 hours. Luciferase activities of triplicate wells were determined using the 
Dual Luciferase Reporter Assay System according to the manufacturer’s protocol 
(Promega). Reporter activities were expressed as relative Firefly/Renilla luciferase 
activities.  
 
Immunoblotting 
Combined cytoplasmic and nuclear extracts were prepared using a high salt 
extraction buffer containing 0.4 Μ NaCl, 0.1% Nonidet P-40, 10 mΜ Tris-HCl (pH 
8.0), 1 mΜ EDTA, 1 mM dithiothreitol, 1 mΜ phenylmethylsulfonyl fluoride and 1× 
protease inhibitory cocktail (Sigma). Protein concentrations were determined by the 
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Bradford method and up to 200 µg cellular protein was subjected to immunoblot 
analyses. Membranes were probed with antibodies against HIF-1α (clone 54/HIF-1α, 
BD Transduction Laboratories), HIF-2α (NB100-122, Novus Biologicals), PHD2 
(NB100-137, Novus Biologicals), REDD1 (Proteintech Group) and β-actin (Sigma). 
Monoclonal antibodies against CA9 (M75) and PHD3 (P3-188e) were kind gifts of S. 
Pastorekova (Bratislava, Slovak Republic) and P. J. Ratcliffe (Oxford, UK), 
respectively. Signals from HRP-coupled secondary antibodies were detected with 
ECL substrate (all Pierce) using a luminescent image analyser (LAS-4000, 
FUJIFILM).  
 
Cell proliferation/viability assays 
Cells (2×104/well) were plated on 96-well plates and allowed to attach before cultures 
were grown at various serum concentrations (0-10% FCS) for an additional period of 
72 hours at 20% or 1% oxygen. Relative viability of cultures was determined by 
cellular conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT). In brief, cells were exposed to MTT (5 µg/ml) for 2 hours at 37°C and 
formazan crystals were solubilized with 50% dimethylsulfoxid, 25% 
dimethylformamide and 10% sodium dodecyl sulphate (pH 4.7). Absorbances at 570 
nm were determined in a 96-well photometer and means of quadruplicates were 
calculated after background substraction. Data is expressed as relative values 
compared to cellular growth of each cell pool at 20% oxygen in the presence of 10% 
FCS. 
 
Histopathologic grade and Immunohistochemistry 
Construction of tissue microarrays (TMA) used for this study has been described 
earlier (Theurillat et al., 2007). Tumor histology was determined according to the 
criteria of the World Health Organization as defined in (Tavassoli and Devilee, 2003). 
Staging of the disease followed (Sobin and Wittekind, 2002), while tumors were 
graded according to the modified Bloom and Richardson system (Elston and Ellis, 
1991). For statistical analyses, only cases with clinical follow-up were considered. 
TMA sections were processed using an automated immunohistochemistry (IHC) 
platform (Benchmark, Ventana, Roche, Illkirch, France). The follwing antibodies and 
dilutions were used: HIF-1α, clone mgc3 (abcam); HIF-2α, NB100-122 (Novus 
MANUSCRIPT 
-71- 
Biologicals); ITPR1, HPA014765 (Sigma); AREG, HPA008720 (Sigma); PAI1, clone 
TJA6 (Leica/Novocastra); WISP2, LS-B917 (Lifespan Biosciences); CA9, ab10471 
(Abcam); GLUT1, AB1340 (Chemicon); KRT5, clone D5/16B4 (Millipore); EGFR, 
clone 3C6 (Ventana); ErbB2, clone 10A7 (Leica/Novocastra); PGR, clone 1A6 
(Millipore) and ESR, clone 6F11 (Ventana). IHC stainings for HIF-α, ESR and PGR 
were evaluated in percent of positive nuclei and expression levels were categorized 
as “low” (<median of overall expression) or “high” (>median of overall expression), 
respectively. Intensities of all other stainings were semiquantitatively scored as 
negative, weakly, moderate or strongly positive (0, 1+, 2+, 3+). Survival analyses 
stratified for AREG and WISP2 expression were performed considering negative and 
weak expression (0, 1+) as “low” and accordingly moderate and strongly positive (2+, 
3+) as “high”. 
 
Bioinformatic analyses and statistical methods 
Cluster analyses and visualization of gene expression data were performed using the 
GenePattern software package hosted on the Broad Institute website 
(http://www.broad.mit.edu/genepattern) (Reich et al., 2006). In brief, mean values of 
quantitative expression data derived from at least three independent hypoxic time 
courses were expressed on a log2 (ratio) scale with highest gene expression levels in 
parental MCF-7 arbitrarily defined as one. Elements were grouped into 6 clusters 
using consensus clustering to define the optimal number of clusters, and cluster 
centres were calculated applying the k-means algorithm. Samples were clustered 
using a hierarchical clustering algorithm and Euclidean distances of samples were 
visualized by dendrograms. In analogy, expression data from 50 cell lines were 
extracted from Kao et al. (Kao et al., 2009) and samples clustered using a 
hierarchical clustering algorithm. Conservation across species of promoter regions 
was evaluated using the MULTIZ whole-genome multiple alignment algorithm 
(Blanchette et al., 2004) implemented in the UCSC Genome Browser 
(http://genome.ucsc.edu). Alignments were manually edited using Genedoc version 
2.6 (http://www.psc.edu/biomed/genedoc). For multiple comparisons, one-way 
ANOVA with Tukey-Kramer’s post hoc test was performed. Column statistics 
applying unpaired Student’s t-tests were calculated using GraphPad Prism version 
4.0 (GraphPad Software). Protein expression data for statistical TMA evaluation were 
analysed in cross tables with χ2 tests. Survival analyses were conducted according to 
Kaplan-Meier with log rank test and multivariate Cox regression analyses (inclusion 
model) using PASW (IBM SPSS Statistics 18) software. Area-proportional Convex 
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Venn-3 diagrams were drawn using Peter Rodger’s (Canterbury, UK) web applet 
(Rodgers et al., 2010). 
MANUSCRIPT 
-73- 
Supplemental References 
 
Blanchette, M., Kent, W. J., Riemer, C., Elnitski, L., Smit, A. F., Roskin, K. M., 
Baertsch, R., Rosenbloom, K., Clawson, H., Green, E. D., et al. (2004). Aligning 
multiple genomic sequences with the threaded blockset aligner. Genome Res 14, 
708-715. 
Bordoli, M. R., Stiehl, D. P., Borsig, L., Kristiansen, G., Hausladen, S., Schraml, P., 
Wenger, R. H., and Camenisch, G. (2010). Prolyl-4-hydroxylase PHD2- and 
hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to 
breast tumorigenesis. Oncogene. 
Elston, C. W., and Ellis, I. O. (1991). Pathological prognostic factors in breast 
cancer. I. The value of histological grade in breast cancer: experience from a large 
study with long-term follow-up. Histopathology 19, 403-410. 
Fritah, A., Redeuilh, G., and Sabbah, M. (2006). Molecular cloning and 
characterization of the human WISP-2/CCN5 gene promoter reveal its 
upregulation by oestrogens. J Endocrinol 191, 613-624. 
Kao, J., Salari, K., Bocanegra, M., Choi, Y. L., Girard, L., Gandhi, J., Kwei, K. A., 
Hernandez-Boussard, T., Wang, P., Gazdar, A. F., et al. (2009). Molecular profiling 
of breast cancer cell lines defines relevant tumor models and provides a resource 
for cancer gene discovery. PLoS One 4, e6146. 
Lee, S. B., Huang, K., Palmer, R., Truong, V. B., Herzlinger, D., Kolquist, K. A., 
Wong, J., Paulding, C., Yoon, S. K., Gerald, W., et al. (1999). The Wilms tumor 
suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 98, 663-
673. 
Metzen, E., Stiehl, D. P., Doege, K., Marxsen, J. H., Hellwig-Burgel, T., and 
Jelkmann, W. (2005). Regulation of the prolyl hydroxylase domain protein 2 
(phd2/egln-1) gene: identification of a functional hypoxia-responsive element. 
Biochem J 387, 711-717. 
Reich, M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., and Mesirov, J. P. (2006). 
GenePattern 2.0. Nat Genet 38, 500-501. 
Rodgers, P., Flower, J., Stapleton, G., and Howse, J. (2010). Drawing Area-
Proportional Venn-3 Diagrams with Convex Polygons, Vol 6170/2010 (Berlin / 
Heidelberg: Springer). 
Sobin, L., and Wittekind, C., eds. (2002). TNM classification of malignant tumours, 6 
edn (New York: John Wiley & Sons). 
Stiehl, D. P., Wirthner, R., Koditz, J., Spielmann, P., Camenisch, G., and Wenger, R. 
H. (2006). Increased prolyl 4-hydroxylase domain proteins compensate for 
decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. 
J Biol Chem 281, 23482-23491. 
Tavassoli, F., and Devilee, P., eds. (2003). World Health Organization Classification 
of Tumours. Pathology and Genetics of Tumours of the Breast and Femal Genital 
Organs. (Lyon: IARC Press). 
Theurillat, J. P., Ingold, F., Frei, C., Zippelius, A., Varga, Z., Seifert, B., Chen, Y. T., 
Jager, D., Knuth, A., and Moch, H. (2007). NY-ESO-1 protein expression in 
primary breast carcinoma and metastases: correlation with CD8+ T-cell and 
CD79a+ plasmacytic/B-cell infiltration. Int J Cancer 120, 2411-2417. 
 
 
 
CONTRIBUTIONS 
-74- 
7  Own contributions to publication and manuscript 
 
MR Bordoli, DP Stiehl, L Borsig, G Kristiansen, S Hausladen, P Schraml, RH 
Wenger and G Camenisch, Prolyl-4-hydroxylase PHD2- and hypoxia-inducible 
factor 2-dependent regulation of amphiregulin contributes to breast 
tumorigenesis, Oncogene. 2010 Sep. 20. [Epub ahead of print] doi: 
10.1038/onc.2010.433 
 
? Everything except shPHD2 single clone generation, shHIF-1α and shHIF-2α 
cell pools, figures 1B, 1D, and CRE site mutation in the AREG promoter.  
 
 
 
DP Stiehl, MR Bordoli, I Abreu-Rodriguez, P Schraml, K Wollenick, G Kristiansen, 
RH Wenger, HIF-2α dependent regulation of autonomous cell growth by the 
AREG-EGFR-ErbB4 axis is associated with significantly improved patient 
survival in human breast cancer (submitted) 
 
? Part of kinetics, mRNA and qRT-PCR leading to figures 1D, 2B and 2C. 
Figures 4A, 6A-B and supplementary Figures 1, 3. Supplementary Table 1.  
 
UNPUBLISHED DATA 
-75- 
8  Unpublished data 
 
8.1 Loss of PHD2 in MCF-7 cells increases cell migration in vitro 
 
8.1.1 Materials and methods 
 
Human MCF-7 breast carcinoma cells were cultured in high-glucose Dulbecco’s 
modified Eagle’s medium (DMEM) (Sigma, Buchs, Switzerland) as described 
previously216. For hypoxia experiments, cells were grown in a gas-controlled glove 
box (InvivO2 400, Ruskinn Technologies, Leeds, UK).  
The migration potential of MCF-7 cells was assessed in a boyden chamber transwell 
assay (8 µm pore filters, 24-well format). 600 µl FCS-containing medium was added 
to the outer chamber. Exponentially growing cells were washed with PBS and 
trypsinized. Next, cells were washed three times in FCS-free medium containing 1% 
BSA, 1 mM CaCl2 and 1 mM MgCl2. Washed cells were resuspended in FCS-free 
medium. 250’000 cells in a maximal volume of 300 µl were then seeded in the inner 
chamber. Plates were incubated 8 hrs in a normal incubator under normoxic or 1% 
O2 conditions.  
After incubation, medium was carefully aspirated and 750 µl of ice-cold MeOH 
added to the outer chamber. Plates were incubated 20 min at 4°C. Afterwards 
MeOH was aspirated and 0.5% crystal violet in 500 µl 20% MeOH added to the 
outer chamber. After 30 min staining at room temperature, crystal violet was washed 
away with water. The upper part of the filter was cleaned with a cotton swap to 
remove non-migrated cells. Migrated cells were quantified at the microscope. 
For in vivo metastasis studies, cells were detached using PBS-EDTA and 5x105 
cells were injected intravenously into nude mice. After 5 weeks mice were sacrificed 
and the lungs perfused and excised for RNA extraction.  
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8.1.2 Results 
 
To investigate the migratory behaviour of MCF-7 shPHD2 cells, we performed a 
boyden chamber migration assay. The two shPHD2 single clones C1 and C7 
showed a significant increase in migration in response to FCS stimulus compared to 
wild type (wt) cells and cells transfected with the control shRNA. This increased 
migration rate could be observed under normoxic as well as under hypoxic 
conditions [Figures 1A and 1B]. Moreover, the PHD2 reconstituted clones #1, #2 and 
#5 showed again a decreased migration potential compared to the shPHD2 clone 
C1. The migration rate of the reconstituted clones did not differ from the one of wt or 
shcontrol cells [Figure 1C]. To exclude the possibility of a clonal artefact due to 
single clone selection, the experiment was repeated using a pool of lentivirally 
transfected shPHD2 cells. The increased migration rate of shPHD2 cells compared 
to the pool of cells transfected with control shRNA was confirmed [Figure 1D]. 
To investigate if the increased migration rate observed in vitro for shPHD2 cells also 
affects in vivo metastasis formation, MCF-7 parental, shPHD2 single clone C1 and 
the shPHD2 pool were injected intravenously into nude mice. After 5 weeks mice 
were terminated and organs excised. Despite the differences seen in vitro, no 
macroscopic metastasis could be observed in any of the animals. Measurements of 
human epithelial cell adhesion molecule (Epcam) mRNA levels in lung material did 
not show any difference between mice injected with parental cells and animals 
injected with shPHD2 cells [data not shown]. 
 
8.1.3 Discussion 
 
We could show that loss of PHD2 in MCF-7 cells significantly increases their 
migration rate in vitro under normoxic as well as hypoxic conditions in response to 
an FCS stimulus. Reconstitution of PHD2 reduced the migration potential again to 
control levels. This enhanced migration might be due to the activation of the 
classical HIF pathway observed after down-regulation of PHD2. Many HIF target 
genes are known to regulate cancer relevant processes like cell migration, cell 
invasion and induction of metastasis. To support our hypothesis, the experiments 
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should be repeated using PHD2/HIF-1α and PHD2/HIF-2α double knock-down cell 
lines. 
Intravenous injection of MCF-7 parental or shPHD2 cells into nude mice did not lead 
to any metastasis formation. From the literature, it is known that MCF-7 breast 
cancer cells are not invasive and only in rare cases induce metastasis. Our 
observations are therefore not surprising and can be explained with the very low 
metastatic potential of the MCF-7 cell line. To investigate the possibility that PHD2 
knock-down cells are more metastatic , experiments should be carried out with a 
more invasive cell line. 
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A)                                                                B) 
Figure 1. PHD2 downregulation increases the migration rate of MCF-7 
cells. A) and B) ShPHD2 clones C1 and C7 showed a significantly increased 
migration compared to shcontrol transfected cells under normoxic (left) as well 
as hypoxic conditions (right). C) PHD2 reconstitution in the clones #1, #2 and 
#5 reduces the migration rate to control levels. D) Increased migration was 
observed in a pool of lentivirally transfected shPHD2 cells. Statistical analysis 
was performed using student t-test: * p < 0.05; ** p < 0.01; *** p < 0.001. 
20% O2 
C)                                                                                  D) 
1% O2 
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8.2 Generation of stable PHD2 and PHD3 knock-down clones in 
MCF-7 and MDA-MB-231 breast cancer cells 
 
8.2.1 Downregulation of PHD3 in MCF-7 cells 
 
In addition to the previously described PHD2 knock-down clones in MCF-7 cells, we 
were also able to generate stable clones downregulating PHD3 in the same cell line. 
From the clone named #1.1 generated by Daniel Stiehl, an additional limited dilution 
with the aim to improve the downregulation of PHD3 was started. Selection of a 
large number of new single clones screened under normoxic as well as under 
dimethyloxaloylglycine (DMOG) treatment did not lead to improved PHD3 
downregulation at the mRNA level. However, clones 3C4 and 3C6 showed reduced 
PHD3 levels compared to levels observed in the parental clone #1.1 [Figure 1A]. To 
further confirm efficiency and stability of the PHD3 downregulation, parental cells, 
clones #1.1, 3C4, 3C6 and #4.1 were incubated under hypoxic condition up to 72 hrs 
and PHD3 mRNA levels measured. Since clone #4.1 only showed a moderate PHD3 
downregulation [data not shown] it was used as a control. Stable low PHD3 mRNA 
levels were confirmed in clones #1.1, 3C4 and 3C6, while late PHD3 induction was 
observed in the clone #4.1 [Figure 1B]. 
 
8.2.2 Double PHD2 and PHD3 downregulation in MCF-7 cells 
 
Starting from stable shPHD2 single clones in MCF-7 cells, we aimed to generate 
stable double knock-downs for PHD2 and PHD3. Interestingly, although many cells 
survived the double antibiotic selection only 1 clone, named #5, showed an efficient 
down-regulation of both PHD isoforms [Figure 2] at the mRNA level. In all other 
selected cells, expression of either PHD2 or PHD3 was restored [data not shown] 
suggesting that concomitant downregulation of both PHD isoforms does not confer a 
selective advantage.  
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8.2.3 Downregulation of PHD3 in MDA-MB-231 
 
As a second breast cancer cell model, we chose to work with the highly invasive and 
metastatic cell line MDA-MB-231. Interestingly, while MCF-7 is a hormone-
dependent cell line expressing both the estrogen as well as the progesterone 
receptor, growth and proliferation of MDA-MB-231 is independent of presence of 
hormones. Therefore, the MDA-MB-231 is negative for both the previously 
mentioned receptors and offers an interesting alternative model to study the effects 
of PHDs downregulation in breast cancer. 
The first aim was the generation of shPHD3 single clones. In contrast to MCF-7, 
where PHD3 mRNA levels are continuously increasing under hypoxia, in MDA-MB-
231 PHD3 mRNA levels seem to peak after 8 hrs hypoxia and decrease again at 
later time points [Figure 3, open bars]. 
Efficient and stable PHD3 down-regulation at the mRNA level could be shown in 
clones C2, C4 and D2 [Figure 3]. 
 
8.2.4 Downregulation of PHD2 in MDA-MB-231 
 
To generate MDA-MB-231 clones downregulating PHD2, we first tried the classical 
approach with polyethyleneimine (PEI)-mediated transfection of the shRNA 
construct, followed by limited dilution under selection pressure. Only few clones 
survived the selection. Out of them, clones B, E and F showed a moderate PHD2 
downregulation at the mRNA level [Figure 4]. Interestingly, the proliferation rate of 
the shPHD2 clones, namely B and E, was strongly reduced compared to parental 
cells [Figure 5]. To exclude clonal artefacts coming from the limited dilution under 
strong selective pressure, the transfection of the shRNA for PHD2 was repeated 
using a lentiviral expression system. With this second attempt a pool of clones 
strongly and efficiently downregulating PHD2 could be generated. The efficiency of 
the downregulation was assessed via immunoblotting as shown in [Figure 6]. The 
effect on cell proliferation observed in the single clones could not be reproduced in 
this pool [data not shown]. 
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8.2.5 Double PHD2 and PHD3 downregulation in MDA-MB-231 
 
The generation of double knock-down of PHD2 and PHD3 starting from stably 
transfected shPHD3 MDA-MB-231 clones was unfortunately unsuccessful. Only a 
few single clones survived the limited dilution under double selection. Subsequent 
mRNA measurements clearly showed that only one PHD isoform was found to be 
convincingly downregulated, whereas the mRNA levels for the second isoform were 
comparable to parental cell levels. Therefore, the double selection led to clones 
strongly down-regulating either PHD2 (clones 3 and 4) or PHD3 (clones 1, 2 and 5) 
[Figure 7]. These results suggest that cells MDA-MB-231 lacking two out of the three 
PHD isoforms might not be viable or might have a very slow proliferation rate, which 
results in overgrowth by other cells. 
A possible alternative approach would be a lentiviral double transfection and 
evaluation of a pool of clones instead of the time consuming and clonal selection 
prone limited dilution. 
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Figure 1. Stable and efficient downregulation of PHD3 in MCF-7 cells.
A) Clone 1.1 was subjected to limited dilution; the new clones 3C4 and 3C6 
showed a comparable down-regulation of PHD3 mRNA, measured by 
quantitative RT-PCR, in normoxia as well as under DMOG treatment. B) 
Hypoxic kinetics (1% O2) of shPHD3 clones showing efficient and stable 
reduction of PHD3 mRNA levels. 
B) 
A) 
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Figure 2. Stable and efficient concomitant downregulation of PHD2 and 
PHD3 in MCF-7 cells. mRNA levels of PHD2 (left panel) and PHD3 (right 
panel) were measured by quantitative RT-PCR. Both PHD2 and PHD3 
mRNA levels were stably and efficiently reduced in clone 5 compared to 
parental cells. 
Figure 3. Stable and efficient downregulation of PHD3 in MDA-MB-231 
cells. PHD3 mRNA levels were measured by quantitative RT-PCR. PHD3
levels were stably and efficiently reduced in the shPHD3 clones C2, C4 and 
D2. 
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Figure 5. Reduced proliferation 
rate of MDA-MB-231 shPHD2 cells. 
Cells were counted every second day 
using a Beckman ViCell cell counter. 
shPHD2 clones B and E show a 
strong reduction in their proliferation 
rate compared to parental cells. 
Figure 4. Stable and efficient downregulation of PHD2 in MDA-MB-231.
PHD2 mRNA levels were measured by quantitative RT-PCR. The single 
clones B, E and F showed stable and efficient downregulation of PHD2 at 
the mRNA level.  
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Figure 7. Simultaneous stable downregulation of PHD2 and PHD3 in 
MDA-MB-231 cells was not achieved. PHD2 (left panel) and PHD3 (right 
panel) mRNA levels were measured in different clones subjected to double 
transfection and double selection. Clones #3 and #4 showed reduced PHD2 
levels, but normal PHD3 levels. Clones #1, #2, and #5 showed an almost 
complete PHD3 downregulation, however PHD2 levels were still high.  
 
 
PHD2  
 
 
β-actin 
        MDA-MB-231 wt                         MDA-MB-231 shPHD2 
pool% oxygen    20      1                                                20   1  
           hrs   72       4      8      24     48    72            72      4       8    24     48 
Figure 6. Stable and efficient lentivirally mediated downregulation of 
PHD2 in MDA-MB-231 cells. Protein was extracted from a pool of lentivirally 
transfected shPHD2 cells and PHD2 protein levels were compared to parental 
cells by immunoblotting. PHD2 was stably and efficiently down-regulated in 
the knock-down pool of clones also under prolonged hypoxia. 
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9  Discussion 
 
9.1 Background 
 
Reduced tissue oxygenation is a common feature of many pathological conditions 
like stroke, ischemia, inflammation and cancer. Most solid tumors are known to be at 
least partially hypoxic. The degree of tumor hypoxia is an important adverse 
prognostic marker. 
The most important players in regulating short-term answers as well as adaptation to 
hypoxia are the hypoxia-inducible transcription factors. The HIF-α subunit is 
hydroxylated in the presence of oxygen by PHD proteins. Hydroxylation at two 
specific proline residues, located within the ODD domain, targets HIF-α for 
degradation. Under hypoxic conditions, absence of oxygen inhibits PHD activity, 
causing HIF-α stabilization and its translocation to nucleus. Nuclear dimerization of 
the HIF-α subunit with the constitutively expressed β subunit and subsequent DNA 
binding at specific HREs triggers the transcription of HIF target genes. Many well 
known HIF target genes are involved in the malignant progression of cancer. Among 
them the chemokine receptor CXCR4 was shown to play an important role in 
determining the metastatic destination of breast cancer cells217, lysyl oxidase (LOX) 
that was shown to be critical for the metastatic niche formation after its secretion 
from hypoxic breast tumors218, 219 and the extensively studied VEGF-A, a key player 
in angiogenesis.  
To investigate the role of PHD2 in the context of breast cancer, we generated stable 
PHD2 knock-down clones in MCF-7 cells. Xenografts experiments in nude mice 
showed a clear correlation between PHD2 levels and tumor size. 
Immunohistochemical analysis of the excised tumors showed a significant higher 
vascularization in the absence of PHD2. Secretion of angiogenic factors like VEGF, 
IL-8 and AREG was found to be modulated by PHD2. Specific HIF-2α and PHD2-
dependent AREG regulation could be confirmed at the mRNA level as well as on the 
promoter level. Our results suggest a role for PHD2 as a tumor suppressor in breast 
cancer. 
 
DISCUSSION 
-87- 
9.2 Role of PHD2 and AREG in breast tumorigenesis 
 
AREG represented an interesting target, since it was first discovered in conditioned 
media of MCF-7 cells220and was recently shown to play an important role in breast 
cancer initiation and progression221, 222. AREG overexpression is often found in 
breast tumors especially in invasive mammary carcinomas223, 224 and was shown to 
induce cell invasion in MCF-10A cells225. Even more important in the context of our 
work was the fact that AREG antisense nucleotides have been used to reverse the 
malignant phenotype of a transformed human breast epithelial cell line in vivo226. 
The observed reduction of tumor mass correlated with a reduced tumor 
vascularization. Also the fact that AREG is a heparin-binding glycoprotein belonging 
to the epidermal growth factor (EGF) family, which binds the epidermal growth factor 
receptor 1 (EGFR)220, makes it an interesting candidate. In fact, EGF signaling is 
one of the most important pathways involved in the development of breast cancer as 
well as in the malignant progression of mammary carcinomas. Although we did not 
specifically investigate if the phenotypic differences in tumorigenesis observed in our 
breast cancer model were entirely due to PHD2-dependent regulation of AREG by 
generation and injection into mice of PHD2/AREG double knock-down clones, we 
could at least provide evidence for the importance of AREG in angiogenesis by in 
vitro tube formation assays. In addition, our mouse experiments and our clinical data 
suggest a role for PHD2 as a tumor suppressor in breast cancer. 
 
9.3 Role of PHD2 and AREG in angiogenesis 
 
Interestingly, the most striking differences seen in in vitro tube formation assays 
concerned the extent and the size of the branching points that were altered after 
downregulation of AREG. This observation is in line with the known developmental 
role of AREG. In fact, AREG was shown to play an essential role during ductal 
morphogenesis in the pubertal mammary gland227 and to induce epithelial branching 
in organ cultures of embryonic mouse kidneys228. Taken together, our results and 
previous studies suggest a specific role for AREG in stimulating the morphogenesis 
of branching substructures in different organs and blood vessels. Since AREG is for 
sure not the most potent angiogenic factor known, it was somehow surprising to 
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observe such a difference in in vitro tube formation. Notably, the clear reduction of 
branching points after addition of the anti-AREG blocking antibody occurred in the 
presence of relatively high levels of VEGF and IL-8, which were also found to be 
increased after downregulation of PHD2. Mechanistically, very little is known on how 
AREG performs its angiogenic function. It has been shown that AREG down-
regulation reduced the expression levels of transforming growth factor β 1 (TGFβ1) 
in a transformed breast epithelial cell model229. A further study proposed a link 
between AREG and tumor necrosis factor α (TNFα) mediated IL-8 upregulation in 
human airway epithelial cells230. We did not investigate, if our described IL-8 
upregulation in the absence of PHD2 was a direct consequence of PHD2 
downregulation, similarly to previously published data214, or a secondary effect due 
to the induction of AREG. 
 
9.4 Role of oxygen in AREG regulation 
 
Since the PHD2 enzymatic function is strongly dependent on pO2 and the main 
PHD2 hydroxylation target, HIF, as well as NF-kB, recently described as a PHD2 
target214, are strongly influenced by oxygen availability, we analyzed the hypoxic 
inducibility of AREG. We could show that AREG mRNA as well as AREG promoter 
activity were not induced under hypoxic conditions (1% O2). However, it remains to 
be analyzed whether AREG is transcriptionally regulated under lower oxygen 
conditions or anoxia. Of note, AREG mRNA levels were unchanged after DMOG 
treatment, a hypoxia mimicking condition. In the literature the effects of oxygen on 
AREG are still unclear. In experiments performed with premature rat lungs as a 
model of BPD, AREG was shown to be induced after hyperoxia231. Microarray 
studies with colon-derived epithelial cells showed an increase in AREG after hypoxic 
exposure (1% O2). This hypoxic upregulation of AREG could be confirmed by RT-
qPCR. Further experiments excluded an involvement of the HIF pathway, but 
showed that the hypoxic AREG induction was depending on cyclic AMP response 
element binding protein (CREB)232.  
In line with the lack of hypoxic induction, we could show that PHD2-mediated 
regulation of AREG promoter activity was not dependent on PHD2 hydroxylation 
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activity. Based on our experimental results, we conclude that AREG transcription in 
MCF-7 breast cancer cells is not affected by oxygen levels. 
 
9.5 Transcriptional regulation of AREG 
 
Mechanistically, we concentrated our efforts on investigating, if the HIF pathway was 
involved in the PHD2-dependent expression of AREG. Activation of the HIF pathway 
is well known to lead to increased angiogenesis through the activation of HIF target 
genes like VEGF. AREG mRNA levels were found to be strongly reduced after HIF-
2α downregulation in MCF-7 cells and weakly induced after HIF-1α downregulation. 
In addition, we could induce AREG promoter activity in a HIF-2α knock-down 
background by exogenous HIF-2α expression, whereas overexpression of HIF-1α 
did not show any effect. We hypothesized that the weak increase in mRNA levels 
observed after HIF-1α down-regulation was probably due to the higher HIF-2α levels 
under these particular conditions. The HIF-2α mediated regulation of AREG has not 
been reported before. AREG transcription has been shown to be induced by the 
Wilms Tumor suppressor (WT) 1 transcription factor during development in a model 
of fetal kidney differentiation228. Moreover, estrogen was also shown to be implicated 
in transcriptional induction of AREG, probably indirectly, since no estrogen-
responsive elements (ERE) were identified in the AREG promoter233. As mentioned 
before, CREB was previously found to be important for hypoxic AREG induction232 
and we could confirm by mutation of the CRE binding site in the AREG promoter that 
CREB affects AREG promoter activity. However, the PHD2 effect on AREG 
promoter activity was maintained despite the mutation of the CRE site. Furthermore, 
REL-A downregulation in PHD2 knock-down cells did not alter mRNA expression of 
AREG, suggesting that in contrast to the published PHD2/NF-κB/IL-8214 or ANG 
axis, PHD2-mediated regulation of AREG does not occur via NF-κB signaling. 
Recently, BRCA1, another fundamental protein involved in breast cancer 
development and progression, has been proposed as a transcriptional repressor of 
AREG further underlying the importance of this gene in the molecular context of 
mammary carcinoma234.  
Moreover, we tried to identify which region of the AREG promoter is essential to 
mediate the HIF-2α effect. Whereas deletion of a major part of the AREG 5’-
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untranslated region (UTR) abolished the HIF-2α-dependent AREG induction, 
transfection of the isolated 5’-UTR failed to confer HIF-2α responsiveness to a 
reporter construct driven by the SV40 minimal promoter. These results suggest that 
the AREG 5’-UTR is necessary but not sufficient to mediate the HIF-2α effect and 
that additional sites might be involved. Conserved sites in the AREG promoter, 
including WT1, CREB, E-box and T-box response elements, were identified by 
phylogenetic foot-print analyses. Only mutation of the WT1 response element (WRE) 
significantly attenuated the specific responsiveness to HIF-2α, whereas mutation of 
the other sites did not influence the HIF-2α effect on the promoter. Although WT1 
was identified as a potent transcriptional activator of the WRE site228, we can 
exclude its involvement since we could not detect any WT1 mRNA expression in our 
cells (data not shown). Absence of WT1 expression in MCF-7 cells was already 
described in a previous study235. Therefore we conclude that AREG expression in 
response to HIF-2α might at least in part be due to an undefined WRE binding 
activity involving direct or indirect HIF-2α binding or binding of other HIF-2α-induced 
transcription factors. 
 
9.6 The HIF-2α/AREG/EGFR axis and autonomous cell growth 
 
Analysis of the phosphorylation status of 16 receptor tyrosine kinases (RTKs) using 
an RTK array, clearly showed that only members of the EGFR family are active in 
MCF-7 cells, namely EGFR, ERBB3 and ERBB4. Furthermore, the phosphorylation 
status of EGFR and ERBB4 was found to be reduced in the absence of HIF-2α 
when compared to parental cells. In the absence of HIF-1α, the phosphorylation 
status of the mentioned receptors was found to be increased, possibly due to higher 
HIF-2α activity in these cells. Importantly, phosphorylation of EGFR and ERBB4 in 
HIF-2α lacking cells could be restored by addition of exogenous AREG. These 
results underline the importance of EGFR signaling in MCF-7 cells and suggest a 
role for HIF-2α in mediating the activation of the EGFR pathway. Although reduced 
EGFR signaling after HIF-2α depletion was recently observed236, to our knowledge, 
AREG provides the first direct link between HIF-2α dependent transcription and 
EGFR family activation in human breast cancer. Moreover, when exposed to low 
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oxygen concentration, HIF-2α depleted cells showed a dramatic retardation in 
proliferation compared to parental cells. Additionally shHIF-2α cells were also found 
to be highly susceptible to serum depletion. Hypoxic conditions associated to 
nutrient deprivation are a common feature of solid tumors and the impaired 
proliferation observed in HIF-2α depleted cells suggest a role for HIF-2α in 
regulating autonomous growth factor signaling. Taken together our data led to the 
conclusion that cells expressing HIF-2α benefit from autocrine and paracrine growth 
factor signaling, which supports cellular autonomy, decreasing the selection 
pressure and possibly slowing tumor progression. Supporting this hypothesis, our 
clinical data showed a significant increased overall survival of patients with high HIF-
2α tumors. Similar observations were recently made in a non-small cell lung cancer 
model, where HIF-2α depletion resulted in an increase of tumor burden237.  
 
9.7 Potential clinical application of PHD inhibitors 
 
Our results as well as other recent studies identified PHD2 as a potential tumor 
suppressor protein. This hypothesis was corroborated by clinical data from patients 
suffering from breast or colon carcinoma as well as from in vivo xenografts 
experiments using various PHD2 down-regulated cell lines214. Since PHD inhibitors 
have been developed as EPO substitutes as well as for the treatment of ischemic 
diseases, potential adverse effects on tumor progression should be taken into 
account. 
In this context however, not only the role of PHD2 in tumor cells, but also the role of 
stromal PHD2 should be considered. In fact, in addition to our results and to the 
already mentioned studies also the influence of “host” PHD2 on tumor growth was 
examined. Using a genetically modified mouse model heterozygous for PHD2, it was 
shown that orthotopic tumors grown into wild-type mice were more invasive and 
prone to generate metastasis compared to tumors grown in a Phd2+/- genetic 
background215. Although no difference could be detected in overall tumor vessel 
density, PHD2 was shown to dramatically influence the morphology of the blood 
vessels. The reduced intravasation of tumor cells into the circulatory system of 
Phd2+/- mice and the consequent reduction of metastatic spread was due to more 
regular, smoother and mature blood vessel compared to the malformed and leaky 
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vessels found in tumors derived from wild-type mice215. Based on these 
observations, one can hypothesize a beneficial effect of PHD2 inhibition in the 
stroma leading to vessel normalization in the tumor and preventing generation of 
distant metastasis. 
Additional studies addressing simultaneously both the effects of silencing PHD2 in 
the host and/or silencing PHD2 in the tumor cells would be of interest to further 
elucidate the complex role of this enzyme in cancer. Furthermore, clinical 
administration of PHD inhibitors for the treatment of non-cancerous diseases should 
be carefully evaluated. Parameters like predisposition to cancer, presence of tumors, 
tumor type as well as systemic or local administration of the drugs should be 
considered. Since application of pan-PHD inhibitors in rats stimulated 
angiogenesis81, clinical trials combining PHD inhibitors together with anti-angiogenic 
compounds might be of interest.  
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